<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease - Fukuda, N - 2023 | Cochrane Library</title> <meta content="Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease - Fukuda, N - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012066.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease - Fukuda, N - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012066.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012066.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Nobuhiko Fukuda" name="citation_author"/> <meta content="Yokohama City University Graduate School of Medicine" name="citation_author_institution"/> <meta content="e103066f@yokohama-cu.ac.jp" name="citation_author_email"/> <meta content="Nobuyuki Horita" name="citation_author"/> <meta content="Yokohama City University Graduate School of Medicine" name="citation_author_institution"/> <meta content="Ayami Kaneko" name="citation_author"/> <meta content="Yokohama City University Graduate School of Medicine" name="citation_author_institution"/> <meta content="Atsushi Goto" name="citation_author"/> <meta content="Center for Public Health Sciences, National Cancer Center" name="citation_author_institution"/> <meta content="Takeshi Kaneko" name="citation_author"/> <meta content="Yokohama City University Graduate School of Medicine" name="citation_author_institution"/> <meta content="Erika Ota" name="citation_author"/> <meta content="St. Luke's International University" name="citation_author_institution"/> <meta content="Kayleigh M Kew" name="citation_author"/> <meta content="Cochrane Central Executive" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD012066.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/06/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012066.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012066.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012066.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [therapeutic use]; Adrenergic beta-2 Receptor Agonists [therapeutic use]; Muscarinic Antagonists; *Pneumonia [drug therapy]; *Pulmonary Disease, Chronic Obstructive [drug therapy]; Quality of Life" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012066.pub3&amp;doi=10.1002/14651858.CD012066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="XwNPMGod";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012066\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012066\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","th","ms","hr","fa","pl","fr","nl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012066.pub3",title:"Long\\u2010acting muscarinic antagonist (LAMA) plus long\\u2010acting beta\\u2010agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease",firstPublishedDate:"Jun 5, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012066.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012066.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012066.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012066.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012066.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012066.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;nl&quot;,&quot;title&quot;:&quot;Samenvatting in eenvoudige taal&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012066.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012066.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012066.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012066.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6781 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012066.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full#CD012066-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full#CD012066-sec-0074"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full#CD012066-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full#CD012066-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full#CD012066-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full#CD012066-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full#CD012066-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full#CD012066-sec-0068"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/appendices#CD012066-sec-0079"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/supinfo/CD012066-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/supinfo/CD012066-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/information#CD012066-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Nobuhiko Fukuda</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/information#CD012066-cr-0005">Nobuyuki Horita</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/information#CD012066-cr-0006">Ayami Kaneko</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/information#CD012066-cr-0007">Atsushi Goto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/information#CD012066-cr-0008">Takeshi Kaneko</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/information#CD012066-cr-0009">Erika Ota</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012066.pub3/information#CD012066-cr-0010">Kayleigh M Kew</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/information/en#CD012066-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 June 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012066.pub3">https://doi.org/10.1002/14651858.CD012066.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012066-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012066-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012066-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012066-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012066-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012066-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012066-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD012066-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012066-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012066-abs-0001" lang="en"> <section id="CD012066-sec-0001"> <h3 class="title" id="CD012066-sec-0001">Background</h3> <p>Long‐acting beta‐agonists (LABAs), long‐acting muscarinic antagonists (LAMAs), and inhaled corticosteroids (ICSs) are inhaled medications used to manage chronic obstructive pulmonary disease (COPD). When two classes of medications are required, a LAMA plus an ICS (LABA+ICS) were previously recommended within a single inhaler as the first‐line treatment for managing stable COPD in people in high‐risk categories. However, updated international guidance recommends a LAMA plus a LABA (LAMA+LABA). This systematic review is an update of a Cochrane Review first published in 2017. </p> </section> <section id="CD012066-sec-0002"> <h3 class="title" id="CD012066-sec-0002">Objectives</h3> <p>To compare the benefits and harms of LAMA+LABA versus LABA+ICS for treatment of people with stable COPD. </p> </section> <section id="CD012066-sec-0003"> <h3 class="title" id="CD012066-sec-0003">Search methods</h3> <p>We performed an electronic search of the Cochrane Airways Group Specialised Register, ClinicalTrials.gov, and the World Health Organization Clinical Trials Search Portal, followed by handsearches. Two review authors screened the selected articles. The most recent search was run on 10 September 2022. </p> </section> <section id="CD012066-sec-0004"> <h3 class="title" id="CD012066-sec-0004">Selection criteria</h3> <p>We included parallel or cross‐over randomised controlled trials of at least one month's duration, comparing LAMA+LABA and LABA+ICS for stable COPD. We included studies conducted in an outpatient setting and irrespective of blinding. </p> </section> <section id="CD012066-sec-0005"> <h3 class="title" id="CD012066-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and evaluated risk of bias. We resolved any discrepancies through discussion. We analysed dichotomous data as odds ratios (ORs), and continuous data as mean differences (MDs), with 95% confidence intervals (CIs) using Review Manager 5. Primary outcomes were: participants with one or more exacerbations of COPD; serious adverse events; quality of life, as measured by the St. George's Respiratory Questionnaire (SGRQ) total score change from baseline; and trough forced expiratory volume in one second (FEV<sub>1</sub>). We used the GRADE framework to rate our certainty of the evidence in each meta‐analysis as high, moderate, low or very low.  </p> </section> <section id="CD012066-sec-0006"> <h3 class="title" id="CD012066-sec-0006">Main results</h3> <p>This review updates the first version of the review, published in 2017, and increases the number of included studies from 11 to 19 (22,354 participants). The median number of participants per study was 700. In each study, between 54% and 91% (median 70%) of participants were males. Study participants had an average age of 64 years and percentage predicted FEV<sub>1</sub> of 51.5% (medians of study means). Included studies had a generally low risk of selection, performance, detection, attrition, and reporting biases. All but two studies were sponsored by pharmaceutical companies, which had varying levels of involvement in study design, conduct, and data analysis. </p> <p><b>Primary outcomes</b> </p> <p>The odds of having an exacerbation were similar for LAMA+LABA compared with LABA+ICS (OR 0.91, 95% CI 0.78 to 1.06; I<sup>2</sup> = 61%; 13 studies, 20,960 participants; moderate‐certainty evidence). The odds of having a serious adverse event were also similar (OR 1.02, 95% CI 0.91 to 1.15; I<sup>2</sup> = 20%; 18 studies, 23,183 participants; high‐certainty evidence). Participants receiving LAMA+LABA had a similar improvement in quality of life, as measured by the SGRQ, to those receiving LABA+ICS (MD ‐0.57, 95% CI ‐1.36 to 0.21; I<sup>2</sup> = 78%; 9 studies, 14,437 participants; moderate‐certainty evidence) but showed a greater improvement in trough FEV<sub>1</sub> (MD 0.07, 95% CI 0.05 to 0.08; I<sup>2</sup> = 73%; 12 studies, 14,681 participants; moderate‐certainty evidence).  </p> <p><b>Secondary outcomes</b> </p> <p>LAMA+LABA decreased the odds of pneumonia compared with LABA+ICS from 5% to 3% (OR 0.61, 95% CI 0.52 to 0.72; I<sup>2</sup> = 0%; 14 studies, 21,829 participants; high‐certainty evidence) but increased the odds of all‐cause death from 1% to 1.4% (OR 1.35, 95% CI 1.05 to 1.75; I<sup>2</sup> = 0%; 15 studies, 21,510 participants; moderate‐certainty evidence). The odds of achieving a minimal clinically important difference of four or more points on the SGRQ were similar between LAMA+LABA and LABA+ICS (OR 1.06, 95% CI 0.90 to 1.25; I<sup>2</sup> = 77%; 4 studies, 13,614 participants; moderate‐certainty evidence). </p> </section> <section id="CD012066-sec-0007"> <h3 class="title" id="CD012066-sec-0007">Authors' conclusions</h3> <p>Combination LAMA+LABA therapy probably holds similar benefits to LABA+ICS for exacerbations and quality of life, as measured by the St George's Respiratory Questionnaire, for people with moderate to severe COPD, but offers a larger improvement in FEV<sub>1</sub> and a slightly lower risk of pneumonia. There is little to no difference between LAMA+LABA and LAMA+ICS in the odds of having a serious adverse event. Whilst all‐cause death may be lower with LABA+ICS, there was a very small number of events in the analysis, translating to a low absolute risk. Findings are based on moderate‐ to high‐certainty evidence from heterogeneous trials with an observation period of less than one year. This review should be updated again in a few years. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012066-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012066-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012066-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012066-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012066-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012066-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012066-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012066-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/nl#CD012066-abs-0020">Nederlands</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012066-abs-0015">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD012066-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012066-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012066-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012066-abs-0002" lang="en"> <h3>Which combination of inhaled medications are safe and effective for chronic obstructive pulmonary disease (COPD)? </h3> <p><b>Key messages</b> </p> <p>• Using an inhaler containing a long‐acting muscarinic antagonist plus a long‐acting beta‐agonist (LAMA+LABA) for chronic obstructive pulmonary disease (COPD) probably improves respiratory function and reduces the risk of pneumonia compared to LABA plus an inhaled corticosteroid (LABA+ICS). </p> <p>• LAMA+LABA and LABA+ICS probably work as well as each other in reducing COPD exacerbations and improving quality of life. </p> <p>• The risk of death was slightly higher in people taking LAMA+LABA.</p> <p><b>What is chronic obstructive pulmonary disease, and how is it treated?</b> </p> <p>Chronic obstructive pulmonary disease (COPD) is a long‐term lung condition characterised by cough, sputum production (fluids from the lungs, i.e. phlegm), and difficulty breathing.  </p> <p>COPD is treated with medications called 'bronchodilators' that make breathing easier by relaxing the muscles in the lungs and widening the airways. Two key types of bronchodilator medicines are long‐acting muscarinic antagonists (LAMAs) and long‐acting beta‐agonists (LABAs). Healthcare guidelines now recommend that people with stable, high‐risk COPD use inhalers containing either a combined LAMA+LABA medicine or a combined LABA plus inhaled corticosteroid (LABA+ICS) medicine. Corticosteroids are anti‐inflammatory medicines. </p> <p><b>What did we want to find out?</b> </p> <p>We examined the findings of trials that randomised people to receive either LAMA+LABA or LABA+ICS to see how they compare. </p> <p><b>What did we do?</b> </p> <p>We searched for trials that explored the benefits and harms of LAMA+LABA and LABA+ICS for the treatment of people with COPD. We summarised these results and rated our confidence in the evidence. </p> <p><b>What did we find?</b> </p> <p>We included 19 studies involving 22,354 participants. The studies lasted from 6 to 52 weeks. The studies included more men than women (approximately 70% of participants were men), and the people in the studies were about 64 years old. Most studies included people with moderate to severe COPD. Pharmaceutical companies were involved in most of the studies, which might affect how much we can trust the results. </p> <p>Compared to LABA+ICS, LAMA+LABA led to an improvement in lung function, reduced pneumonia from 5% to 3% but increased the risk of death from 1% to 1.4%. LAMA+LABA probably made little to no difference to COPD exacerbations (flare‐ups) compared to LABA+ICS. People in each of the treatment groups reported similar quality of life scores and were about as likely to experience serious side effects, which were rare.  </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the evidence was moderate to high because the included studies were well‐designed and had a sufficient number of participants with mainly moderate to severe COPD. </p> <p><b>How up to date is this evidence?</b> </p> <p>This review is up to date to 10 September 2022. The results from future or ongoing trials evaluating newly developed medicines are awaited. This review should be updated again in a few years. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012066-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012066-sec-0074"></div> <h3 class="title" id="CD012066-sec-0075">Implications for practice</h3> <section id="CD012066-sec-0075"> <p>Combined long‐acting muscarinic antagonist (LAMA) and long‐acting beta‐agonist (LABA) inhalers probably hold similar benefits to LABA plus inhaled corticosteroid (ICS) inhalers for exacerbations and quality of life (as measured by the St George's Respiratory Questionnaire) for people with moderate to severe chronic obstructive pulmonary disease (COPD), but offer a larger improvement in forced expiratory volume in one second (FEV<sub>1</sub>)and a lower risk of pneumonia. Clinicians need to consider pneumonia as an underlying cause when people with COPD using LABA plus ICS (LABA+ICS) inhalers have exacerbations. All‐cause death may be lower with LABA+ICS. However, there was a very small number of events in the analysis, which means absolute risk was low. Findings are based on moderate‐ to high‐certainty evidence from heterogeneous trials with an observation period of less than one year.  </p> <p>The choice between LAMA+LABA and LABA+ICS may need to take account of the individual's condition, including blood eosinophil count, history of pneumonia, and recent exacerbations. This review should be updated again in a few years. </p> </section> <h3 class="title" id="CD012066-sec-0076">Implications for research</h3> <section id="CD012066-sec-0076"> <p>Further research is indicated to clarify the relative positions of LABA+ICS and LAMA+LABA in the COPD treatment guidelines. Trials should exclude people with asthma and should rapidly switch participants from any prior treatment to trial treatment to reduce the number of people who withdraw from the study. Longer‐term follow‐up data would be beneficial, especially to identify any impact on serious adverse events or mortality. Results from future or ongoing trials evaluating newly developed bronchodilators are awaited. Meta‐analyses that access the data for each combined medication separately are also anticipated. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012066-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012066-sec-0008"></div> <div class="table" id="CD012066-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>LAMA plus LABA versus LABA plus ICS for stable COPD</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people with stable COPD<br/><b>Setting:</b> outpatient. Studies were conducted in &gt; 50 countries including low‐, medium‐, and high‐income countries from all continents<br/><b>Intervention:</b> LAMA+LABA<br/><b>Comparison:</b> LABA+ICS </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>LABA+ICS</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>LAMA+LABA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations (number of people experiencing ≥ 1 exacerbations)</p> <p>Follow‐up: 6 to 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>291 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>272 per 1000 (243 to 303)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.91<br/>(0.78 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,960<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a‐e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low OR means favourable outcome</p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (number of people experiencing ≥ 1 SAEs)</p> <p>Follow‐up: 6 to 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000 (136 to 166)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.02<br/>(0.91 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,183<br/>(18 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High<sup>b,c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low OR means favourable outcome. Herth 2020 was discarded as no events were reported in either arm. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life as measured by SGRQ total score change from baseline (MD)</p> <p>Follow‐up: 12 to 52 weeks</p> <p>Scale 0 to 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.57</p> <p>(1.36 lower to 0.21 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,437</p> <p>(9 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a‐e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low MD means favourable outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trough FEV<sub>1</sub> change from baseline </p> <p>Follow‐up: 6 to 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.07 L</p> <p>(0.05 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,681</p> <p>(12 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a,b,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High MD means favourable outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia</p> <p>Follow‐up: 12 to 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000 (24 to 33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.61<br/>(0.52 to 0.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,829<br/>(14 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High<sup>b,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low OR means favourable outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause death</p> <p>Follow‐up: 6 to 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000 (11 to 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.35<br/>(1.05 to 1.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,510<br/>(15 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b,d,e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low OR means favourable outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SGRQ total score change from baseline</p> <p>(≥ 4 points, MCID)</p> <p>Follow‐up: 26 to 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>373 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>387 per 1000 (349 to 427)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.06</p> <p>(0.90 to 1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,614</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a‐e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High OR means favourable outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>absolute risk</b> (and its 95% CI) of LAMA+LABA group is based on the assumed risk in the LABA+ICS group and the <b>OR</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>ICS:</b> inhaled corticosteroid; <b>LABA:</b> long‐acting beta‐agonist; <b>LAMA:</b> long‐acting muscarinic antagonist; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>SGRQ:</b> St. George's Respiratory Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of effect but may be substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>There was a considerable heterogeneity, I<sup>2</sup> &gt; 50%.<br/><sup>b</sup>Studies varied in their inclusion criteria around recent history of exacerbation, baseline percentage predicted FEV<sub>1</sub> and exclusion of asthma. No indirectness downgrades, but impacts interpretation and applicability of results (see <a href="#CD012066-sec-0068">Discussion</a>).<br/><sup>c</sup>Confidence interval includes benefit of either treatment but lies within predefined threshold for clinical importance (0.7 to 1.5 for OR outcomes; 4‐point MCID for SGRQ) ‐ no downgrade for imprecision<br/><sup>d</sup>No downgrades for publication bias. Funnel plots examined for primary outcomes (exacerbations, serious adverse events, SGRQ, FEV<sub>1</sub>) do not show obvious asymmetry (see Figure 3; Figure 3; Figure 4; Figure 6). Nearly all studies included in pneumonia and all‐cause death analyses. Only 4 studies included in SGRQ 4+ change analysis but not specified in most studies. <br/><sup>e</sup>No downgrades for risk of bias. Across outcomes, all or almost all studies were at high risk of 'other' bias due to conflicts of interest, and studies contributing between 18.5% and 35.9% of the analysis weight were rated high risk of bias in at least one other domain. We did not prespecify a threshold or specific domains for downgrading, but considered it insufficient to downgrade if studies contributing more than half the analysis weight were at low or unclear risk of bias in all but the 'other' domain.<br/><sup>f</sup>There was imprecision due to a low number of events. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012066-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012066-sec-0009"></div> <section id="CD012066-sec-0010"> <h3 class="title" id="CD012066-sec-0010">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is characterised by bronchial obstruction, systemic inflammation, and comorbidities. It is the third leading cause of death worldwide, with more than 3.23 million people dying due to COPD each year (<a href="./references#CD012066-bbs2-0075" title="World Health Organization. Global health estimates: life expectancy and leading causes of death and disability. www.who.int/data/gho/data/themes/mortality-and-global-health-estimates (accessed 1 January 2022).">WHO 2019</a>). In addition to active tobacco smoking, indoor biomass smoke, outdoor air pollution, and occupational exposure also play a role in the development of COPD. The most common symptoms of COPD – shortness of breath on exertion and cough – are present for a prolonged period and typically worsen over time (<a href="./references#CD012066-bbs2-0055" title="The Global Initiative for Chronic Obstructive Lung Disease. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023. www.goldcopd.org/2023-gold-report-2/ (accessed 15 December 2022).">GOLD 2023</a>). </p> <p>Since the late 1960s, the definition of COPD has repeatedly been modified. Early definitions of COPD included chronic bronchitis, which is clinically characterised by chronic cough, and emphysema, which is pathologically defined by damaged sacs or alveoli in the lungs (<a href="./references#CD012066-bbs2-0048" title="BurrowsB , FletcherCM , HeardBE , JonesNL , WootliffJS . The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet1966;1(7442):830-5. [DOI: 10.1016/s0140-6736(66)90181-4] [PMID: 4159957]">Burrows 1966</a>). In 2001, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) released its first report, Global Strategy for the Diagnosis, Management, and Prevention of COPD (<a href="./references#CD012066-bbs2-0067" title="PauwelsRA , BuistAS , CalverleyPM , JenkinsCR , HurdSS , GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. American Journal of Respiratory and Critical Care Medicine2001;163(5):1256-76. [DOI: 10.1164/ajrccm.163.5.2101039] [PMID: 11316667]">Pauwels 2001</a>), which supported the definition of COPD, indicating that the disorder is recognised primarily by chronic obstruction of lung airflow (<a href="./references#CD012066-bbs2-0067" title="PauwelsRA , BuistAS , CalverleyPM , JenkinsCR , HurdSS , GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. American Journal of Respiratory and Critical Care Medicine2001;163(5):1256-76. [DOI: 10.1164/ajrccm.163.5.2101039] [PMID: 11316667]">Pauwels 2001</a>). </p> <p>If COPD is properly diagnosed and managed, symptoms can be ameliorated. Smoking cessation, smoke‐free cooking, vaccination, and an active lifestyle are the first steps in COPD management, and daily pharmacological treatment is required for most people with symptomatic stable COPD (<a href="./references#CD012066-bbs2-0055" title="The Global Initiative for Chronic Obstructive Lung Disease. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023. www.goldcopd.org/2023-gold-report-2/ (accessed 15 December 2022).">GOLD 2023</a>). </p> </section> <section id="CD012066-sec-0011"> <h3 class="title" id="CD012066-sec-0011">Description of the intervention</h3> <p>While asymptomatic individuals with mild airflow limitations can be treated with on‐demand short‐acting bronchodilators, key medications for symptomatic COPD management consist of three classes of inhaled medication: long‐acting beta‐agonists (LABAs), long‐acting muscarinic antagonists (LAMAs), and inhaled corticosteroids (ICSs) (<a href="./references#CD012066-bbs2-0055" title="The Global Initiative for Chronic Obstructive Lung Disease. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023. www.goldcopd.org/2023-gold-report-2/ (accessed 15 December 2022).">GOLD 2023</a>). If the disease cannot be adequately controlled with LAMA or LABA monotherapy, administration of two or more medications from different classes may prove beneficial. When two classes of medication are required, a LAMA plus a LABA (LAMA+LABA) or a LABA plus an ICS (LABA+ICS) are often selected because these combinations can be administered via a single medication device (<a href="./references#CD012066-bbs2-0053" title="FramptonJE . QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs2014;74(4):465-88. [DOI: 10.1007/s40265-014-0194-8] [PMID: 24604791]">Frampton 2014</a>; <a href="./references#CD012066-bbs2-0062" title="MalerbaM , MorjariaJB , RadaeliA . Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD - role of umeclidinium/vilanterol. International Journal of Chronic Obstructive Pulmonary Disease2014;9:687-95. [DOI: 10.2147/COPD.S47792] [PMID: 25061288]">Malerba 2014</a>; <a href="./references#CD012066-bbs2-0064" title="NanniniLJ , PooleP , MilanSJ , HolmesR , NormansellR . Combined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 11. Art. No: CD003794. [DOI: 10.1002/14651858.CD003794.pub4] [PMID: 24214176]">Nannini 2013</a>; <a href="./references#CD012066-bbs2-0070" title="SchachterEN . Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD. Drugs Today2013;49(7):437-6. [DOI: 10.1358/dot.2013.49.7.1980496] [PMID: 23914352]">Schachter 2013</a>), which is most beneficial for improving patient adherence (<a href="./references#CD012066-bbs2-0061" title="HoritaN , KanekoT . Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan. International Journal of Chronic Obstructive Pulmonary Disease2015;10:813-22. [DOI: 10.2147/COPD.S56067] [PMID: 25960646]">Horita 2015a</a>). </p> </section> <section id="CD012066-sec-0012"> <h3 class="title" id="CD012066-sec-0012">How the intervention might work</h3> <p>Currently, there are no medications that can cure COPD. Thus, the practical goal of COPD treatment is to control the symptoms, reduce the frequency of exacerbations, and improve exercise tolerance and quality of life. COPD treatment usually consists of smoking cessation, vaccination, inhaled bronchodilators, ICSs, oral medication, long‐term oxygen therapy, and pulmonary rehabilitation (<a href="./references#CD012066-bbs2-0055" title="The Global Initiative for Chronic Obstructive Lung Disease. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023. www.goldcopd.org/2023-gold-report-2/ (accessed 15 December 2022).">GOLD 2023</a>). According to the GOLD approach, people are classified into three categories depending on the degree of symptoms and the risk of exacerbations (<a href="./references#CD012066-bbs2-0055" title="The Global Initiative for Chronic Obstructive Lung Disease. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023. www.goldcopd.org/2023-gold-report-2/ (accessed 15 December 2022).">GOLD 2023</a>). Medications belonging to a specific class are recommended based on the following criteria: </p> <p> <ul id="CD012066-list-0001"> <li> <p>Category A (low symptoms plus few exacerbations): bronchodilator (short‐ or long‐acting); consider switching to another depending on response; </p> </li> <li> <p>Category B (high symptoms plus few exacerbations): LAMA+LABA;</p> </li> <li> <p>Category E (high symptoms plus many exacerbations): LAMA+LABA; LAMA+LABA+ICS is considered if blood eosinophil count is high. </p> </li> </ul> </p> <section id="CD012066-sec-0013"> <h4 class="title">Long‐acting muscarinic antagonists</h4> <p>LAMAs dilate the airway by selectively blocking acetylcholine M<sub>3</sub> receptors and inhibiting bronchoconstriction (<a href="./references#CD012066-bbs2-0045" title="AlaghaK , PalotA , SofalviT , PahusL , GouitaaM , TumminoC , et al. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Therapeutic Advances in Chronic Disease2014;5(2):85-98. [DOI: 10.1177/2040622313518227] [PMID: 24587893]">Alagha 2014</a>). Since the early 2000s, LAMAs, especially tiotropium, have been regarded as the first‐choice medication for treating COPD. LAMAs confer anti‐inflammatory effects and, more importantly, anti‐airway remodelling effects (<a href="./references#CD012066-bbs2-0073" title="TashkinDP , CooperCB . The role of long-acting bronchodilators in the management of stable COPD. Chest2004;125(1):249-59. [DOI: 10.1378/chest.125.1.249] [PMID: 14718448]">Tashkin 2004</a>). </p> </section> <section id="CD012066-sec-0014"> <h4 class="title">Long‐acting beta‐agonists</h4> <p>LABAs widen the airway by relaxing the airway muscles. Studies have suggested that LABAs may also provide anti‐inflammatory and protective effects against bronchoconstrictive substances. Regular use of a short‐acting beta‐agonist that works quickly and lasts for four to six hours is not currently recommended for people with asthma or COPD. A LABA that lasts for approximately 12 to 24 hours is considered a maintenance medication (<a href="./references#CD012066-bbs2-0046" title="AndersonR , TheronAJ , SteelHC , DurandtC , TintingerGR , FeldmanC . The beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro. Mediators of Inflammation2014;2014:105420. [DOI: 10.1155/2014/105420] [PMID: 24733958]">Anderson 2014</a>; <a href="./references#CD012066-bbs2-0073" title="TashkinDP , CooperCB . The role of long-acting bronchodilators in the management of stable COPD. Chest2004;125(1):249-59. [DOI: 10.1378/chest.125.1.249] [PMID: 14718448]">Tashkin 2004</a>). </p> </section> <section id="CD012066-sec-0015"> <h4 class="title">Inhaled corticosteroids</h4> <p>ICSs reduce airway inflammation. Although ICSs are indicated for bronchial asthma, in which eosinophils play a key role, they are not as effective when neutrophils are observed in the airways of people with COPD (<a href="./references#CD012066-bbs2-0047" title="BarnesPJ . Inhaled corticosteroids in COPD: a controversy. Respiration2010;80(2):89-95. [DOI: 10.1159/000315416] [PMID: 20501985]">Barnes 2010</a>; <a href="./references#CD012066-bbs2-0058" title="HananiaNA . The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulmonary Pharmacology and Therapeutics2008;21(3):540-50. [DOI: 10.1016/j.pupt.2007.12.004] [PMID: 18280761]">Hanania 2008</a>; <a href="./references#CD012066-bbs2-0071" title="SuissaS , BarnesPJ . Inhaled corticosteroids in COPD: the case against. European Respiratory Journal2009;34(1):13-6. [DOI: 10.1183/09031936.00190908] [PMID: 19567599]">Suissa 2009</a>). The previous GOLD report recommended that ICSs be prescribed in combination with LABA for people with COPD with severe airflow limitation or with a high risk of exacerbations (<a href="./references#CD012066-bbs2-0054" title="The Global Initiative for Chronic Obstructive Lung Disease. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. www.goldcopd.org/Guidelines/guidelines-resources.html (accessed 7 December 2016).">GOLD 2016</a>). Studies have suggested that LABA+ICS may be highly effective for people with a high sputum/blood eosinophil count (<a href="./references#CD012066-bbs2-0066" title="PascoeS , LocantoreN , DransfieldMT , BarnesNC , PavordID . Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respiratory Medicine2015;3(6):435-42. [DOI: 10.1016/S2213-2600(15)00106-X] [PMID: 25878028]">Pascoe 2015</a>). </p> </section> </section> <section id="CD012066-sec-0016"> <h3 class="title" id="CD012066-sec-0016">Why it is important to do this review</h3> <p>The previous GOLD report recommended the first‐line use of ICSs only for people with severe to very severe airflow limitation and two or more exacerbations per year, with one or more hospitalisations for exacerbations (<a href="./references#CD012066-bbs2-0054" title="The Global Initiative for Chronic Obstructive Lung Disease. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. www.goldcopd.org/Guidelines/guidelines-resources.html (accessed 7 December 2016).">GOLD 2016</a>). That report suggested that ICSs reduce the risk of exacerbations (<a href="./references#CD012066-bbs2-0054" title="The Global Initiative for Chronic Obstructive Lung Disease. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. www.goldcopd.org/Guidelines/guidelines-resources.html (accessed 7 December 2016).">GOLD 2016</a>). Nonetheless, prescription rates for ICSs and combined LABA+ICS agents are high (<a href="./references#CD012066-bbs2-0050" title="DrivenesE , OstremA , MelbyeH . Predictors of ICS/LABA prescribing in COPD patients: a study from general practice. BMC Family Practice2014;15:42. [DOI: 10.1186/1471-2296-15-42] [PMID: 24597538]">Drivenes 2014</a>; <a href="./references#CD012066-bbs2-0074" title="WhiteP , ThorntonH , PinnockH , GeorgopoulouS , BoothHP . Overtreatment of COPD with inhaled corticosteroids - implications for safety and costs: cross-sectional observational study. PLoS One2013;8(10):e75221. [DOI: 10.1371/journal.pone.0075221] [PMID: 24194824]">White 2013</a>). This is probably because many randomised controlled trials (RCTs) have supported the hypothesis that the salmeterol (LABA) plus fluticasone propionate (ICS) combination – the oldest combination treatment – can improve quality of life, especially for people with dyspnoea, and can also decrease acute exacerbations of COPD and reduce yearly declines in pulmonary function (<a href="./references#CD012066-bbs2-0054" title="The Global Initiative for Chronic Obstructive Lung Disease. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. www.goldcopd.org/Guidelines/guidelines-resources.html (accessed 7 December 2016).">GOLD 2016</a>). Blood and sputum eosinophil counts can serve as predictive biomarkers for differentiating between people with COPD who will derive the greatest benefit from ICS administration and people who will not benefit from an ICS (<a href="./references#CD012066-bbs2-0066" title="PascoeS , LocantoreN , DransfieldMT , BarnesNC , PavordID . Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respiratory Medicine2015;3(6):435-42. [DOI: 10.1016/S2213-2600(15)00106-X] [PMID: 25878028]">Pascoe 2015</a>). The <a href="./references#CD012066-bbs2-0055" title="The Global Initiative for Chronic Obstructive Lung Disease. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023. www.goldcopd.org/2023-gold-report-2/ (accessed 15 December 2022).">GOLD 2023</a> report now recommends LAMA+LABA+ICS only for people with category E COPD who have a high eosinophil count, and recommends that ICSs should not be over‐prescribed in COPD cases. </p> <p>Understanding which type of combination treatment (LAMA+LABA or LABA+ICS) is most beneficial for people with COPD, regardless of eosinophil count, is important, and this systematic review contributes to answering this question. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012066-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012066-sec-0017"></div> <p>To compare the benefits and harms of LAMA+LABA versus LABA+ICS for treatment of people with stable COPD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012066-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012066-sec-0018"></div> <section id="CD012066-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012066-sec-0020"> <h4 class="title">Types of studies</h4> <p>We planned to include individually‐randomised and cluster‐randomised controlled trials and cross‐over trials, but not quasi‐RCTs. We included studies reported as full text, those published as abstract only, and unpublished data. When we could not obtain sufficient data from published articles, we contacted authors and sponsors, and accessed trial registration websites. We included open‐label, single‐blinded, and double‐blinded studies. The minimum accepted trial duration was one month. </p> </section> <section id="CD012066-sec-0021"> <h4 class="title">Types of participants</h4> <p>We included adults with a diagnosis of COPD according to GOLD guidelines (<a href="./references#CD012066-bbs2-0055" title="The Global Initiative for Chronic Obstructive Lung Disease. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023. www.goldcopd.org/2023-gold-report-2/ (accessed 15 December 2022).">GOLD 2023</a>). We did not set specific exclusion criteria involving comorbidities. We planned to exclude original studies focusing on asthma‐COPD overlap syndrome (ACOS). </p> </section> <section id="CD012066-sec-0022"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing LAMA+LABA versus LABA+ICS. We permitted treatments administered via a single combined device or via two separate devices. We excluded trials of short‐acting bronchodilators (e.g. ipratropium). We included co‐interventions when they were not part of the randomly assigned treatment. </p> </section> <section id="CD012066-sec-0023"> <h4 class="title">Types of outcome measures</h4> <section id="CD012066-sec-0024"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012066-list-0002"> <li> <p>Exacerbations (participants with one or more)</p> </li> <li> <p>Serious adverse events (participants with one or more)</p> </li> <li> <p>Quality of life, as measured by the St. George's Respiratory Questionnaire (SGRQ) total score change from baseline </p> </li> <li> <p>Trough forced expiratory volume in one second (FEV<sub>1</sub>) change from baseline </p> </li> </ul> </p> </section> <section id="CD012066-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012066-list-0003"> <li> <p>Pneumonia (participants with one or more occurrences); assessed based on chest x‐ray</p> </li> <li> <p>All‐cause death</p> </li> <li> <p>SGRQ total score change from baseline (4 points or greater)</p> </li> <li> <p>Hospitalisations for COPD exacerbations (participants with one or more occurrences)</p> </li> </ul> </p> </section> </section> </section> <section id="CD012066-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012066-sec-0027"> <h4 class="title">Electronic searches</h4> <p>We identified trials from the Cochrane Airways Group Specialised Register (CAGR), which is maintained by the Information Specialist for the Group. The Register contains trial reports identified through systematic searches of bibliographic databases, including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Allied and Complementary Medicine Database (AMED), and PsycINFO, and through handsearching of respiratory journals and conference abstracts (see <a href="./appendices#CD012066-sec-0080">Appendix 1</a> for details). We searched all records in the CAGR from the date it was last searched for the previous version of this review (2 February 2016) to 10 September 2022, using the search strategy provided in <a href="./appendices#CD012066-sec-0085">Appendix 2</a>. </p> <p>We conducted a search of ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>) and the World Health Organization (WHO) Clinical Trials Search Portal (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>), from the date they were last searched (4 June 2016) to 10 September 2022 (<a href="./appendices#CD012066-sec-0086">Appendix 3</a>; <a href="./appendices#CD012066-sec-0087">Appendix 4</a>). </p> <p>We searched all databases from their inception, and we imposed no restrictions on language of publication. </p> </section> <section id="CD012066-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all primary studies and review articles for additional references, and we searched relevant manufacturers' websites for trial information. We searched for errata or retractions from included studies published as full text on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>). Handsearches were done up to 1 November 2021. </p> </section> </section> <section id="CD012066-sec-0029"> <h3 class="title" id="CD012066-sec-0029">Data collection and analysis</h3> <section id="CD012066-sec-0030"> <h4 class="title">Selection of studies</h4> <p>We used Cochrane’s Screen4Me workflow to help assess the search results. Screen4Me comprises three components: (1) known assessments – a service that matches records in the search results to records that have already been screened in Cochrane Crowd and labelled as an RCT or 'Not an RCT'; (2) the RCT classifier – a machine learning model that distinguishes RCTs from non‐RCTs; and (3) if appropriate, Cochrane Crowd – Cochrane’s citizen science platform where the Crowd helps to identify and describe health evidence. For more information about Screen4Me and the evaluations that have been done, please visit the Screen4Me webpage on the Cochrane Information Specialists' portal: <a href="https://community.cochrane.org/organizational-info/resources/resources-groups/information-specialists-portal" target="_blank">community.cochrane.org/organizational-info/resources/resources-groups/information-specialists-portal</a>. </p> <p>Two review authors (NF and NH) independently screened the titles and abstracts of all studies identified by the search for possible inclusion, and coded studies as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We retrieved the full‐text publications. Two review authors (NF and NH) independently screened the full texts to identify studies for inclusion and recorded reasons for exclusion of ineligible studies. We resolved disagreements through discussion, or, when required, we consulted a third review author (TK). We identified and excluded duplicates and collated multiple reports of the same study, so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) flow diagram and a <a href="./references#CD012066-sec-0112" title="">Characteristics of excluded studies</a> table (<a href="./references#CD012066-bbs2-0063" title="MoherD , LiberatiA , TetzlaffJ , AltmanD . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097] [PMID: 19621072]">Moher 2009</a>). </p> </section> <section id="CD012066-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form that had been piloted on at least one study in the review to document study characteristics and outcome data. Two review authors (NF and NH) extracted the following study characteristics from the included studies. </p> <p> <ul id="CD012066-list-0004"> <li> <p>Methods: study design, duration of study follow‐up and 'run‐in' period, number of study centres and countries, and study start date. </p> </li> <li> <p>Participants: number, mean and standard deviation (SD) age, gender, mean and SD of baseline FEV<sub>1</sub> key inclusion criteria, number of participants randomised and completed, and follow‐up duration. </p> </li> <li> <p>Interventions: intervention, comparison, and dosage of the intervention.</p> </li> <li> <p>Outcomes: primary outcomes specified and collected and time points reported.</p> </li> <li> <p>Notes: funding for trial and notable conflicts of interest (COI) of trial authors, trial registration, and other information if necessary. </p> </li> </ul> </p> <p>Two review authors (NF and NH) independently extracted outcome data from the included studies. We noted in the <a href="./references#CD012066-sec-0111" title="">Characteristics of included studies</a> table if outcome data were not reported in a useable way. We resolved disagreements by consensus or by consultation with a third review author (TK). One review author (NF) transferred data into Review Manager 5 (<a href="./references#CD012066-bbs2-0069" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). We double‐checked that data were entered correctly by comparing data presented in the systematic review versus data provided in study reports. A second review author (NH) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD012066-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (NF and NH) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012066-bbs2-0060" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We resolved disagreements by discussion or by consultation with another review author (EO). We assessed risk of bias according to the following domains: </p> <p> <ul id="CD012066-list-0005"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other bias.</p> </li> </ul> </p> <p>We graded each potential source of bias as high, low, or unclear and provided an explanation from the study report together with a justification for our judgement in the risk of bias table. We summarised risk of bias judgements across studies for each of the domains listed. We classified outcomes as subjective and objective to consider different risks of performance and selection bias for different blinding methods. All‐cause death is the only outcome of interest to this review that may be considered truly objective and the SGRQ is the only subjective, self‐reported measure. The other outcomes (exacerbations, serious adverse events, FEV<sub>1</sub> and pneumonia) might be considered semi‐objective: they involve a degree of patient reporting, behaviour, or clinician judgement that could introduce bias (intentionally or otherwise) if the randomised treatment had been inadvertently detected through side effects or other means. For example, this could happen in the grading of an adverse event as serious or non‐serious, effort given when measuring FEV<sub>1</sub>, or the interpretation of a chest X‐ray to determine pneumonia. When we requested information on risk of bias related to unpublished data or corresponded with a trialist, we noted this in the risk of bias table. </p> <p>When considering treatment effects, we took into account risk of bias for studies that contributed to that outcome. </p> <section id="CD012066-sec-0033"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the previously published protocol (<a href="./references#CD012066-bbs2-0076" title="HoritaN , GotoA , OtaE , NakashimaK , NagaiK , KanekoT . Long-acting muscarinic antagonist plus long-acting beta agonist versus long-acting beta agonist plus inhaled corticosteroid for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2016, Issue 2. Art. No: CD012066. [DOI: 10.1002/14651858.CD012066]">Horita 2016</a>). </p> </section> </section> <section id="CD012066-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios (ORs), and continuous data as MDs with 95% confidence intervals (CIs). We entered data presented as a scale with a consistent direction of effect (i.e. data in the LAMA+LABA arm minus data in the LABA+ICS arm). Although there is no universal rule to interpret the magnitude of the therapeutic effect from ORs, we believe that an OR greater than 1.5 and an OR of less than 0.7 mean that there is a considerable chance that the outcome is clinically important. </p> <p>We undertook meta‐analyses only when this was meaningful (i.e. if treatments, participants, and the underlying clinical question were similar enough for pooling to make sense). </p> <p>We had planned to describe skewed data using medians and interquartile ranges; however, we found no report describing skewed data. </p> <p>According to the original protocol, when multiple trial arms were reported in a single trial, we included only the relevant arms. </p> </section> <section id="CD012066-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>We analysed the number of participants, not the number of events, as the unit of analysis for dichotomous data (i.e. participants with one or more events). For continuous data, we used MDs. </p> </section> <section id="CD012066-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>We tried to contact investigators, study sponsors, and registration websites to verify key study characteristics and to obtain missing numerical outcome data when possible (e.g. when a study was only reported in an abstract format). When this was not possible, and when missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results by conducting a sensitivity analysis. </p> </section> <section id="CD012066-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I<sup>2</sup> statistic to measure heterogeneity amongst the trials in each analysis: 0% to 40%: might not be important; 30% to 60%: might represent moderate heterogeneity; 50% to 90%: might represent substantial heterogeneity; 75% to 100%: might show considerable heterogeneity (<a href="./references#CD012066-bbs2-0060" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). When we identified considerable heterogeneity, we reported this and explored possible causes by performing a prespecified subgroup analysis.  </p> </section> <section id="CD012066-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>We created and examined a funnel plot to explore possible small‐study and publication biases for the primary outcomes. </p> </section> <section id="CD012066-sec-0039"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model and performed a sensitivity analysis by using a fixed‐effect model (see <a href="#CD012066-sec-0041">Sensitivity analysis</a>). </p> </section> <section id="CD012066-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned the following subgroup analyses for all primary and secondary outcomes:</p> <p> <ul id="CD012066-list-0006"> <li> <p>LAMA+LABA: 'combined indacaterol + glycopyrronium bromide (IND/GLY)' versus 'combined umeclidinium + vilanterol (UMEC/VI)' versus 'other LAMA/LABA inhalers'. </p> </li> <li> <p>COPD severity: 'including only mild or moderate (or both) (% predicted FEV<sub>1</sub> 50% or greater)' versus 'including severe and/or very severe (% predicted FEV<sub>1</sub> less than 50%)' versus 'including both categories.' </p> </li> </ul> </p> <p>We were unable to perform the COPD severity subgroup analysis because separate data for participants with different severities were not reported.  </p> <p>We used the I<sup>2</sup> test to detect heterogeneity, as discussed in <a href="./references#CD012066-bbs2-0059" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557] [PMID: 12958120]">Higgins 2003</a>. We used the formal test for subgroup differences provided in Review Manager 5 (<a href="./references#CD012066-bbs2-0069" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </section> <section id="CD012066-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses using a fixed‐effect model for the primary outcomes and reported any important differences compared with results using the random‐effects model. </p> </section> <section id="CD012066-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created a summary of findings table to present the following outcomes:</p> <p> <ul id="CD012066-list-0007"> <li> <p>exacerbations (participants with one or more);</p> </li> <li> <p>serious adverse events (participants with one or more);</p> </li> <li> <p>quality of life, as measured by the St. George's Respiratory Questionnaire (SGRQ) total score change from baseline; </p> </li> <li> <p>trough FEV<sub>1</sub> change from baseline; </p> </li> <li> <p>pneumonia (participants with one or more occurrences);</p> </li> <li> <p>all‐cause death;</p> </li> <li> <p>SGRQ total score change from baseline (4 points or greater).</p> </li> </ul> </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of a body of evidence (very low, low, moderate, and high certainty of evidence) as it related to studies that contributed data to meta‐analyses for prespecified outcomes (<a href="./references#CD012066-bbs2-0057" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [DOI: 10.1136/bmj.39489.470347.AD] [PMID: 18436948]">Guyatt 2008</a>). We used the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012066-bbs2-0060" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), with <a href="./references#CD012066-bbs2-0056" title="GRADEpro GDT. Version 3.2 for Windows. Hamilton (ON): McMaster University, 2008. Available at gradepro.org.">GRADEpro</a> software (<a href="./references#CD012066-bbs2-0056" title="GRADEpro GDT. Version 3.2 for Windows. Hamilton (ON): McMaster University, 2008. Available at gradepro.org.">GRADEpro</a>). We justified all decisions to downgrade or upgrade the certainty of the evidence by using footnotes, and we provided comments to aid readers' understanding of the review when necessary. </p> <p>We did not prespecify specific domains or percentages for downgrading due to risk of bias, but considered it reasonable to downgrade if studies contributing more than half the analysis weight were at high risk of bias in the 'other bias' domain and at least one other domain. For inconsistency, we downgraded if I<sup>2</sup> was greater than 50%. For imprecision, we based downgrade decisions on prespecified thresholds (clinical importance 0.7 to 1.5 for outcomes as odds ratios) or established minimal clinically important differences (MCIDs) (4 points for SGRQ). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012066-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012066-sec-0043"></div> <section id="CD012066-sec-0044"> <h3 class="title">Description of studies</h3> <p>See <a href="#CD012066-sec-0046">Included studies</a> (<a href="#CD012066-tbl-0002">Table 1</a>), <a href="#CD012066-sec-0049">Excluded studies</a>, and <a href="./references#CD012066-bbs1-0003" title="">Ongoing studies</a>. </p> <div class="table" id="CD012066-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LAMA+LABA</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LABA+ICS</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Key inclusion criteria</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up duration (weeks)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean/median age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number randomised</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0001" title="BeehKM , DeromE , Echave-SustaetaJ , GrönkeL , HamiltonA , ZhaiD , et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study). International Journal of Chronic Obstructive Pulmonary Disease2016;11:193-205. [DOI: 10.2147/COPD.S95055] [PMID: 26893551]DeromE , BeehK , Echave-SustaetaJ , GrönkeL , ZhaiD , BjermerL . Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use. European Respiratory Journal2016;48:PA978. [DOI: 10.1183/13993003.congress-2016]">Beeh 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium/olodaterol (2.5/5 μg) or tiotropium/olodaterol (5/5 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/250 μg) twice daily or salmeterol/fluticasone (50/500 μg) twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 80% Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 × 4 time periods (cross‐over)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0002" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umeclidinium/vilanterol (62.5/25 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/250 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 70%, mMRC ≥ 2, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>707</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0003" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umeclidinium/vilanterol (62.5/25 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/250 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 70%, mMRC ≥ 2, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>700</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0004" title="Ferguson GT,  Rabe KF,  Martinez FJ,  Fabbri LM,  Wang C,  Ichinose M,  et al . Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respiratory Medicine2018;10:747-58. [DOI: 10.1016/S2213-2600(18)30327-8] [PMID: 30232048]JPRN-JapicCTI-184079. A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort Turbuhaler as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PT010006). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184079. JPRN-JapicCTI-184080. A Randomized, Double-Blind, Parallel-Group, 28-Week, Chronic-Dosing, Multi-Center, Extension Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With Symbicort Turbuhaler as an Active Control (PT010007). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184080. NCT03262012. Study to assess the safety and efficacy of PT010, PT003, and PT009 in Japanese subjects with COPD compared with Symbicort Turbohaler. ClinicalTrials.gov/show/NCT03262012 (first posted 25 August 2017). ">Ferguson 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycopyrronium/formoterol fumarate (18/9.6 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol/budesonide/ fumarate (160/4.8 μg)  twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAT ≥ 10, %pred FEV<sub>1</sub> 25% to 80%, not required to have exacerbation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>943</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0005" title="Frith PA,  Ashmawi S,  Krishnamurthy S,  Gurgun A,  Hristoskova S,  Pilipovic V,  et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology2018;12:1152-9. [DOI: 10.1111/resp.13374] [PMID: 30074294]">Frith 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycopyrronium/indacaterol (50/110 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAT ≥ 10, %pred FEV1 30% to 80%, Ex(+)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>502</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0006" title="Herth F,  Hohlfeld JM,  Haas J,  Hoz A,  Jin X,  Kreitner K-F,  et al. The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD. BMJ Open Respiratory Research2020;7(1):e000741. [DOI: 10.1136/bmjresp-2020-000741] [PMID: 33268341]">Herth 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium/olodaterol (5/5 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone  (50/500 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> &lt; 70%, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0007" title="HoshinoM , OhtawaJ , AkitsuK . Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics2015;30:128-33. [DOI: 10.1016/j.pupt.2014.08.002] [PMID: 25183687]">Hoshino 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium/indacaterol (18/150 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/250 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 80%, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0008" title="LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. European Respiratory Journal2018;52:PA4385. [DOI: 10.1183/13993003.congress-2018.PA4385]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. European Respiratory Journal2018;52:PA4384. [DOI: 10.1183/13993003.congress-2018.PA4384]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ . Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. Pneumologie2019;73(Suppl 1):[no pagination]. Lipson DA,  Barnhart F,  Brealey N,  Brooks J,  Criner GJ,  Day NC,  et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine2018;378(18):1671-80. [DOI: 10.1056/NEJMoa1713901] [PMID: 29668352]">Lipson 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umeclidinium/vilanterol (62.5/25 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vilanterol/fluticasone furoate (25/100 μg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAT ≥ 10, %pred FEV<sub>1</sub> &lt; 80%, Ex(+) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6204</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0009" title="MagnussenH , MaltaisF , SchmidtH , KestenS , MetzdorfN . Comparison of tiotropium+salmeterol vs. fluticasone+salmeterol on lung volumes, exercise tolerance and locus of symptom limitation. American Journal of Respiratory and Critical Care Medicine2010;181:A4472. MagnussenH , PaggiaroP , SchmidtH , KestenS , MetzdorfN , MaltaisF . Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respiratory Medicine2012;106(10):1413-20. [DOI: 10.1016/j.rmed.2012.05.011] [PMID: 22749044]">Magnussen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium/salmeterol (18/50 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> ≤ 65%, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 x 2 time periods (cross‐over)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>344</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0010" title="Mostafa TM,  El-Azab GA,  Atia GA,  Lotfy NS. The effectiveness of 3 combined therapeutic regimens in Egyptian patients with moderate-to-severe chronic obstructive pulmonary disease: a randomized double-blind prospective pilot study. Current Therapeutic Research Clinical and Experimental2021;94:100625. [DOI: 10.1016/j.curtheres.2021.100625] [PMID: 34306265]">Mostafa 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium (18 μg) once daily/formoterol (9 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol/budesonide (160/4.5 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 80%, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0011" title="NCT03240575. The ENERGITO 2 study compares 2 inhaled medicines for chronic obstructive pulmonary disease (COPD). One medicine is a combination of tiotropium and olodaterol (Stiolto) taken using the Respimat inhaler and the other medicine is a combination of fluticasone and salmeterol taken using the Diskus. ClinicalTrials.gov/show/NCT03240575 (first posted 7 August 2017). ">NCT03240575</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium (5μg)/olodaterol (5μg) once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50μg/250μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 80%, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>302</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0012" title="RabeKF , TimmerW , SagkriotisA , VielK . Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest2008;134(2):255-62. [DOI: 10.1378/chest.07-2138] [PMID: 18403672]RabeKF , TimmerW , SagriotisA , VielK . Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. In: European Respiratory Society 15th Annual Congress; 2005 Sep 17-20; Copenhagen. 2005. ">Rabe 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium/formoterol (18/24 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> ≤ 65%, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>605</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0013" title="Rabe KF,  Martinez FJ,  Ferguson GT, Wang C,  Singh D,  Wedzicha JA,  et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New England Journal of Medicine2020;383(1):35-48. [DOI: 10.1056/NEJMoa1916046] [PMID: 32579807]">Rabe 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Glycopyrronium/formoterol (9/4.8 µg)  twice daily.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol/budesonide (4.8/160 µg) twice daily.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 25‐65%, CAT ≥ 10, Ex(+) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4294</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0014" title="SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. European Respiratory Journal2014;44(Suppl 58):P290. SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulmonary Medicine2015;15:91. [DOI: 10.1186/s12890-015-0092-1] [PMID: 26286141]">Singh 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umeclidinium/vilanterol (62.5/25 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 70%, mMRC ≥ 2, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>717</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0015" title="BatemanE , VogelmeierC , ChenH , BanerjiD . Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study. American College of Chest Physicians2014;145(3):409A. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 demonstrates superior lung function compared to twice-daily salmeterol/fluticasone in all subgroups of COPD patients: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4273. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 improves breathlessness and reduces rescue medication use compared to twice-daily salmeterol/fluticasone in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A2433. MezziK , PallanteJ , AlagappanV , ChenH , BanerjiD . Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β2-agonist/inhaled corticosteroid (LABA/ICS): the ILLUMINATE study. Chest2014;145(3):424A. VogelmeierC , BatemanE , PallanteJ , BryantH , AlagappanVD , AndreaP , et al. Once-daily QVA149 provides superior bronchodilation and improves lung function versus twice-daily fluticasone/salmeterol in COPD patients: the ILLUMINATE study. British Thoracic Society Winter Meeting2012;67:A149, P194. VogelmeierC , BatemanED , PallanteJ , BryantH , AlagappanV , D'Andrea, et al. QVA149 once daily is safe and well tolerated in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1477. VogelmeierCD , BatemanED , D'AndreaP , MezziK , ChenH , BanerjiD , et al. Once-daily QVA149 is more effective than twice-daily salmeterol/fluticasone in improving lung function, in patients with severe chronic obstructive pulmonary disease (COPD): the illuminate study. American Journal of Respiratory and Critical Care Medicine2014;189:A3763. VogelmeierCF , BatemanED , PallanteJ , AlagappanVK , D'AndreaP , ChenH , et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respiratory Medicine2013;1(1):51-60. [DOI: 10.1016/S2213-2600(12)70052-8] [PMID: 24321804]">Vogelmeier 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indacaterol/glycopyrronium bromide (110/50 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 80%, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>523</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0016" title="GreulichT , KostikasK , GagaM , Aalamian-MattheisM , LossiNS , Patalano  F, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. International Journal of Chronic Obstructive Pulmonary Disease2018;13:1229-37. [DOI: 10.2147/COPD.S159732] [PMID: 29713156]VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenA , et al. The efficacy and safety of aclidinium/formoterol fixed-dose combination compared with salmeterol/fluticasone in patients with COPD: results from a phase III study. American Journal of Respiratory and Critical Care Medicine2015;191:A3974. VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenAM , et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal2016;48(4):1030-9. [DOI: 10.1183/13993003.00216-2016] [PMID: 27492833]">Vogelmeier 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aclidinium/formoterol (400/12 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> &lt; 80%, CAT ≥ 10, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>933</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0017" title="VogelmeierCF , GagaM , Aalamian-MattheisM , GreulichT , MarinJM , CastellaniW , et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research2018;18(1):140. [DOI: 10.1186/s12931-017-0622-x] [PMID: 28720132]">Vogelmeier 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycopyrronium/Indacaterol (50/110 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>any</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 50% ‐80%, mMRC ≥ 1, Ex(+) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1083</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0018" title="KwaijtaalM , WedzichaJ , DecramerM , VestboJ , BanerjiD . Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. Respirology  2014;TP:177. WedzichaJ , VestboJ , GallagherN , BanerjiD . A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study. Chest2014;145(3):408A. WedzichaJA , BanerjiD , ChapmanKR , VestboJ , RocheN , AyersRT , et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. New England Journal of Medicine2016;374(23):2222-34. [DOI: 10.1056/NEJMoa1516385] [PMID: 27181606]">Wedzicha 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indacaterol/glycopyrronium bromide (110/50 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 25% to 60%, mMRC ≥ 2, Ex(+) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3362</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0019" title="ZhongN , WangC , ZhouX , ZhangN , HumphriesM , WangL , et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2015;10:1015-26. [DOI: 10.2147/COPD.S84436] [PMID: 26082625]">Zhong 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indacaterol/glycopyrronium bromide (110/50 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 80%, mMRC ≥ 2, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>744</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>%pred FEV<sub>1</sub>:</b> % predicted forced expiratory volume in one second; <b>CAT:</b> chronic obstructive pulmonary disease assessment test; <b>Ex(‐):</b> without recent exacerbation; <b>Ex(+):</b> with recent exacerbation; <b>LABA:</b> long‐acting beta‐agonist; <b>LAMA:</b> long‐acting muscarinic antagonist; <b>mMRC:</b> modified Medical Research Council dyspnoea scale </p> </div> </div> <section id="CD012066-sec-0045"> <h4 class="title">Results of the search</h4> <p>We identified a total of 2685 records from update searches of electronic databases conducted on 1 November 2021 and 10 September 2022, including ClinicalTrials.gov and the WHO Clinical Trials Search Portal. We found an additional 20 records through manual searches. After removing 1248 duplicate records, there were 1458 records eligible for screening. The Screen4Me workflow removed 376 records, and we excluded 1046 records after viewing titles and abstracts alone. We excluded a further 21 after viewing full texts, which comprised 17 new excluded studies and four records identified as duplicates of records that had already been included. The remaining 15 records met the inclusion criteria for the review, corresponding to eight new included studies and one ongoing study. </p> <p>Thus, we have included a total of 19 studies in the quantitative synthesis in the review (11 studies in the previous version of the review plus eight new included studies; see <a href="#CD012066-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012066-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram" data-id="CD012066-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram</p> </div> </div> </div> </section> <section id="CD012066-sec-0046"> <h4 class="title">Included studies</h4> <p>The 19 studies included 22,354 participants. Seventeen studies used a parallel‐group design and two used a cross‐over design (<a href="./references#CD012066-bbs2-0009" title="MagnussenH , MaltaisF , SchmidtH , KestenS , MetzdorfN . Comparison of tiotropium+salmeterol vs. fluticasone+salmeterol on lung volumes, exercise tolerance and locus of symptom limitation. American Journal of Respiratory and Critical Care Medicine2010;181:A4472. MagnussenH , PaggiaroP , SchmidtH , KestenS , MetzdorfN , MaltaisF . Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respiratory Medicine2012;106(10):1413-20. [DOI: 10.1016/j.rmed.2012.05.011] [PMID: 22749044]">Magnussen 2012</a>; <a href="./references#CD012066-bbs2-0017" title="VogelmeierCF , GagaM , Aalamian-MattheisM , GreulichT , MarinJM , CastellaniW , et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research2018;18(1):140. [DOI: 10.1186/s12931-017-0622-x] [PMID: 28720132]">Vogelmeier 2017</a>), with an 84‐day washout period between treatments. All studies delivered treatment in a double‐blind manner, except two open‐label studies (<a href="./references#CD012066-bbs2-0007" title="HoshinoM , OhtawaJ , AkitsuK . Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics2015;30:128-33. [DOI: 10.1016/j.pupt.2014.08.002] [PMID: 25183687]">Hoshino 2015</a>; <a href="./references#CD012066-bbs2-0017" title="VogelmeierCF , GagaM , Aalamian-MattheisM , GreulichT , MarinJM , CastellaniW , et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research2018;18(1):140. [DOI: 10.1186/s12931-017-0622-x] [PMID: 28720132]">Vogelmeier 2017</a>). </p> <p>The number of participants included in each study ranged from 40 to 6204, with a median of 700 participants per study. Thirteen studies included participants with moderate to severe COPD without recent exacerbation. Four trials that included only participants with a recent exacerbation accounted for 65% of the total participants. In each study, between 54% and 91% (median 70%) of participants were males. The mean age of the participants in each study ranged from 61 to 71 years (median 64 years). The percent predicted (%pred) FEV<sub>1</sub> in each study ranged from 43% to 64%, with a median of 51.5%. </p> <section id="CD012066-sec-0047"> <h5 class="title">Treatment</h5> <p>Treatment duration ranged from six to 52 weeks. Of the LABA+ICS treatments used in these studies, 14 studies used combined salmeterol/fluticasone propionate (<a href="./references#CD012066-bbs2-0001" title="BeehKM , DeromE , Echave-SustaetaJ , GrönkeL , HamiltonA , ZhaiD , et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study). International Journal of Chronic Obstructive Pulmonary Disease2016;11:193-205. [DOI: 10.2147/COPD.S95055] [PMID: 26893551]DeromE , BeehK , Echave-SustaetaJ , GrönkeL , ZhaiD , BjermerL . Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use. European Respiratory Journal2016;48:PA978. [DOI: 10.1183/13993003.congress-2016]">Beeh 2016</a>; <a href="./references#CD012066-bbs2-0002" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015a</a>; <a href="./references#CD012066-bbs2-0003" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015b</a>; <a href="./references#CD012066-bbs2-0005" title="Frith PA,  Ashmawi S,  Krishnamurthy S,  Gurgun A,  Hristoskova S,  Pilipovic V,  et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology2018;12:1152-9. [DOI: 10.1111/resp.13374] [PMID: 30074294]">Frith 2018</a>; <a href="./references#CD012066-bbs2-0006" title="Herth F,  Hohlfeld JM,  Haas J,  Hoz A,  Jin X,  Kreitner K-F,  et al. The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD. BMJ Open Respiratory Research2020;7(1):e000741. [DOI: 10.1136/bmjresp-2020-000741] [PMID: 33268341]">Herth 2020</a>; <a href="./references#CD012066-bbs2-0007" title="HoshinoM , OhtawaJ , AkitsuK . Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics2015;30:128-33. [DOI: 10.1016/j.pupt.2014.08.002] [PMID: 25183687]">Hoshino 2015</a>; <a href="./references#CD012066-bbs2-0009" title="MagnussenH , MaltaisF , SchmidtH , KestenS , MetzdorfN . Comparison of tiotropium+salmeterol vs. fluticasone+salmeterol on lung volumes, exercise tolerance and locus of symptom limitation. American Journal of Respiratory and Critical Care Medicine2010;181:A4472. MagnussenH , PaggiaroP , SchmidtH , KestenS , MetzdorfN , MaltaisF . Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respiratory Medicine2012;106(10):1413-20. [DOI: 10.1016/j.rmed.2012.05.011] [PMID: 22749044]">Magnussen 2012</a>; <a href="./references#CD012066-bbs2-0011" title="NCT03240575. The ENERGITO 2 study compares 2 inhaled medicines for chronic obstructive pulmonary disease (COPD). One medicine is a combination of tiotropium and olodaterol (Stiolto) taken using the Respimat inhaler and the other medicine is a combination of fluticasone and salmeterol taken using the Diskus. ClinicalTrials.gov/show/NCT03240575 (first posted 7 August 2017). ">NCT03240575</a>; <a href="./references#CD012066-bbs2-0012" title="RabeKF , TimmerW , SagkriotisA , VielK . Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest2008;134(2):255-62. [DOI: 10.1378/chest.07-2138] [PMID: 18403672]RabeKF , TimmerW , SagriotisA , VielK . Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. In: European Respiratory Society 15th Annual Congress; 2005 Sep 17-20; Copenhagen. 2005. ">Rabe 2008</a>; <a href="./references#CD012066-bbs2-0014" title="SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. European Respiratory Journal2014;44(Suppl 58):P290. SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulmonary Medicine2015;15:91. [DOI: 10.1186/s12890-015-0092-1] [PMID: 26286141]">Singh 2015</a>; <a href="./references#CD012066-bbs2-0015" title="BatemanE , VogelmeierC , ChenH , BanerjiD . Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study. American College of Chest Physicians2014;145(3):409A. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 demonstrates superior lung function compared to twice-daily salmeterol/fluticasone in all subgroups of COPD patients: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4273. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 improves breathlessness and reduces rescue medication use compared to twice-daily salmeterol/fluticasone in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A2433. MezziK , PallanteJ , AlagappanV , ChenH , BanerjiD . Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β2-agonist/inhaled corticosteroid (LABA/ICS): the ILLUMINATE study. Chest2014;145(3):424A. VogelmeierC , BatemanE , PallanteJ , BryantH , AlagappanVD , AndreaP , et al. Once-daily QVA149 provides superior bronchodilation and improves lung function versus twice-daily fluticasone/salmeterol in COPD patients: the ILLUMINATE study. British Thoracic Society Winter Meeting2012;67:A149, P194. VogelmeierC , BatemanED , PallanteJ , BryantH , AlagappanV , D'Andrea, et al. QVA149 once daily is safe and well tolerated in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1477. VogelmeierCD , BatemanED , D'AndreaP , MezziK , ChenH , BanerjiD , et al. Once-daily QVA149 is more effective than twice-daily salmeterol/fluticasone in improving lung function, in patients with severe chronic obstructive pulmonary disease (COPD): the illuminate study. American Journal of Respiratory and Critical Care Medicine2014;189:A3763. VogelmeierCF , BatemanED , PallanteJ , AlagappanVK , D'AndreaP , ChenH , et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respiratory Medicine2013;1(1):51-60. [DOI: 10.1016/S2213-2600(12)70052-8] [PMID: 24321804]">Vogelmeier 2013</a>; <a href="./references#CD012066-bbs2-0016" title="GreulichT , KostikasK , GagaM , Aalamian-MattheisM , LossiNS , Patalano  F, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. International Journal of Chronic Obstructive Pulmonary Disease2018;13:1229-37. [DOI: 10.2147/COPD.S159732] [PMID: 29713156]VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenA , et al. The efficacy and safety of aclidinium/formoterol fixed-dose combination compared with salmeterol/fluticasone in patients with COPD: results from a phase III study. American Journal of Respiratory and Critical Care Medicine2015;191:A3974. VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenAM , et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal2016;48(4):1030-9. [DOI: 10.1183/13993003.00216-2016] [PMID: 27492833]">Vogelmeier 2016</a>; <a href="./references#CD012066-bbs2-0018" title="KwaijtaalM , WedzichaJ , DecramerM , VestboJ , BanerjiD . Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. Respirology  2014;TP:177. WedzichaJ , VestboJ , GallagherN , BanerjiD . A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study. Chest2014;145(3):408A. WedzichaJA , BanerjiD , ChapmanKR , VestboJ , RocheN , AyersRT , et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. New England Journal of Medicine2016;374(23):2222-34. [DOI: 10.1056/NEJMoa1516385] [PMID: 27181606]">Wedzicha 2016</a>; <a href="./references#CD012066-bbs2-0019" title="ZhongN , WangC , ZhouX , ZhangN , HumphriesM , WangL , et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2015;10:1015-26. [DOI: 10.2147/COPD.S84436] [PMID: 26082625]">Zhong 2015</a>), three studies used combined formoterol/budesonide (<a href="./references#CD012066-bbs2-0004" title="Ferguson GT,  Rabe KF,  Martinez FJ,  Fabbri LM,  Wang C,  Ichinose M,  et al . Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respiratory Medicine2018;10:747-58. [DOI: 10.1016/S2213-2600(18)30327-8] [PMID: 30232048]JPRN-JapicCTI-184079. A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort Turbuhaler as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PT010006). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184079. JPRN-JapicCTI-184080. A Randomized, Double-Blind, Parallel-Group, 28-Week, Chronic-Dosing, Multi-Center, Extension Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With Symbicort Turbuhaler as an Active Control (PT010007). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184080. NCT03262012. Study to assess the safety and efficacy of PT010, PT003, and PT009 in Japanese subjects with COPD compared with Symbicort Turbohaler. ClinicalTrials.gov/show/NCT03262012 (first posted 25 August 2017). ">Ferguson 2018</a>; <a href="./references#CD012066-bbs2-0010" title="Mostafa TM,  El-Azab GA,  Atia GA,  Lotfy NS. The effectiveness of 3 combined therapeutic regimens in Egyptian patients with moderate-to-severe chronic obstructive pulmonary disease: a randomized double-blind prospective pilot study. Current Therapeutic Research Clinical and Experimental2021;94:100625. [DOI: 10.1016/j.curtheres.2021.100625] [PMID: 34306265]">Mostafa 2021</a>; <a href="./references#CD012066-bbs2-0013" title="Rabe KF,  Martinez FJ,  Ferguson GT, Wang C,  Singh D,  Wedzicha JA,  et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New England Journal of Medicine2020;383(1):35-48. [DOI: 10.1056/NEJMoa1916046] [PMID: 32579807]">Rabe 2020</a>), and one study used combined vilanterol/fluticasone furoate (<a href="./references#CD012066-bbs2-0008" title="LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. European Respiratory Journal2018;52:PA4385. [DOI: 10.1183/13993003.congress-2018.PA4385]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. European Respiratory Journal2018;52:PA4384. [DOI: 10.1183/13993003.congress-2018.PA4384]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ . Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. Pneumologie2019;73(Suppl 1):[no pagination]. Lipson DA,  Barnhart F,  Brealey N,  Brooks J,  Criner GJ,  Day NC,  et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine2018;378(18):1671-80. [DOI: 10.1056/NEJMoa1713901] [PMID: 29668352]">Lipson 2018</a>). One study permitted any type or dose of LABA+ICS (<a href="./references#CD012066-bbs2-0017" title="VogelmeierCF , GagaM , Aalamian-MattheisM , GreulichT , MarinJM , CastellaniW , et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research2018;18(1):140. [DOI: 10.1186/s12931-017-0622-x] [PMID: 28720132]">Vogelmeier 2017</a>). Of the administered LAMA+LABA treatments, five studies used glycopyrronium/indacaterol (<a href="./references#CD012066-bbs2-0005" title="Frith PA,  Ashmawi S,  Krishnamurthy S,  Gurgun A,  Hristoskova S,  Pilipovic V,  et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology2018;12:1152-9. [DOI: 10.1111/resp.13374] [PMID: 30074294]">Frith 2018</a>; <a href="./references#CD012066-bbs2-0015" title="BatemanE , VogelmeierC , ChenH , BanerjiD . Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study. American College of Chest Physicians2014;145(3):409A. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 demonstrates superior lung function compared to twice-daily salmeterol/fluticasone in all subgroups of COPD patients: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4273. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 improves breathlessness and reduces rescue medication use compared to twice-daily salmeterol/fluticasone in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A2433. MezziK , PallanteJ , AlagappanV , ChenH , BanerjiD . Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β2-agonist/inhaled corticosteroid (LABA/ICS): the ILLUMINATE study. Chest2014;145(3):424A. VogelmeierC , BatemanE , PallanteJ , BryantH , AlagappanVD , AndreaP , et al. Once-daily QVA149 provides superior bronchodilation and improves lung function versus twice-daily fluticasone/salmeterol in COPD patients: the ILLUMINATE study. British Thoracic Society Winter Meeting2012;67:A149, P194. VogelmeierC , BatemanED , PallanteJ , BryantH , AlagappanV , D'Andrea, et al. QVA149 once daily is safe and well tolerated in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1477. VogelmeierCD , BatemanED , D'AndreaP , MezziK , ChenH , BanerjiD , et al. Once-daily QVA149 is more effective than twice-daily salmeterol/fluticasone in improving lung function, in patients with severe chronic obstructive pulmonary disease (COPD): the illuminate study. American Journal of Respiratory and Critical Care Medicine2014;189:A3763. VogelmeierCF , BatemanED , PallanteJ , AlagappanVK , D'AndreaP , ChenH , et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respiratory Medicine2013;1(1):51-60. [DOI: 10.1016/S2213-2600(12)70052-8] [PMID: 24321804]">Vogelmeier 2013</a>; <a href="./references#CD012066-bbs2-0017" title="VogelmeierCF , GagaM , Aalamian-MattheisM , GreulichT , MarinJM , CastellaniW , et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research2018;18(1):140. [DOI: 10.1186/s12931-017-0622-x] [PMID: 28720132]">Vogelmeier 2017</a>; <a href="./references#CD012066-bbs2-0018" title="KwaijtaalM , WedzichaJ , DecramerM , VestboJ , BanerjiD . Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. Respirology  2014;TP:177. WedzichaJ , VestboJ , GallagherN , BanerjiD . A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study. Chest2014;145(3):408A. WedzichaJA , BanerjiD , ChapmanKR , VestboJ , RocheN , AyersRT , et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. New England Journal of Medicine2016;374(23):2222-34. [DOI: 10.1056/NEJMoa1516385] [PMID: 27181606]">Wedzicha 2016</a>; <a href="./references#CD012066-bbs2-0019" title="ZhongN , WangC , ZhouX , ZhangN , HumphriesM , WangL , et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2015;10:1015-26. [DOI: 10.2147/COPD.S84436] [PMID: 26082625]">Zhong 2015</a>), four studies used umeclidinium/vilanterol (<a href="./references#CD012066-bbs2-0002" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015a</a>; <a href="./references#CD012066-bbs2-0003" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015b</a>; <a href="./references#CD012066-bbs2-0008" title="LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. European Respiratory Journal2018;52:PA4385. [DOI: 10.1183/13993003.congress-2018.PA4385]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. European Respiratory Journal2018;52:PA4384. [DOI: 10.1183/13993003.congress-2018.PA4384]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ . Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. Pneumologie2019;73(Suppl 1):[no pagination]. Lipson DA,  Barnhart F,  Brealey N,  Brooks J,  Criner GJ,  Day NC,  et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine2018;378(18):1671-80. [DOI: 10.1056/NEJMoa1713901] [PMID: 29668352]">Lipson 2018</a>; <a href="./references#CD012066-bbs2-0014" title="SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. European Respiratory Journal2014;44(Suppl 58):P290. SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulmonary Medicine2015;15:91. [DOI: 10.1186/s12890-015-0092-1] [PMID: 26286141]">Singh 2015</a>), two studies used tiotropium/formoterol (<a href="./references#CD012066-bbs2-0012" title="RabeKF , TimmerW , SagkriotisA , VielK . Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest2008;134(2):255-62. [DOI: 10.1378/chest.07-2138] [PMID: 18403672]RabeKF , TimmerW , SagriotisA , VielK . Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. In: European Respiratory Society 15th Annual Congress; 2005 Sep 17-20; Copenhagen. 2005. ">Rabe 2008</a>; <a href="./references#CD012066-bbs2-0010" title="Mostafa TM,  El-Azab GA,  Atia GA,  Lotfy NS. The effectiveness of 3 combined therapeutic regimens in Egyptian patients with moderate-to-severe chronic obstructive pulmonary disease: a randomized double-blind prospective pilot study. Current Therapeutic Research Clinical and Experimental2021;94:100625. [DOI: 10.1016/j.curtheres.2021.100625] [PMID: 34306265]">Mostafa 2021</a>), three studies used tiotropium/olodaterol (<a href="./references#CD012066-bbs2-0001" title="BeehKM , DeromE , Echave-SustaetaJ , GrönkeL , HamiltonA , ZhaiD , et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study). International Journal of Chronic Obstructive Pulmonary Disease2016;11:193-205. [DOI: 10.2147/COPD.S95055] [PMID: 26893551]DeromE , BeehK , Echave-SustaetaJ , GrönkeL , ZhaiD , BjermerL . Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use. European Respiratory Journal2016;48:PA978. [DOI: 10.1183/13993003.congress-2016]">Beeh 2016</a>; <a href="./references#CD012066-bbs2-0006" title="Herth F,  Hohlfeld JM,  Haas J,  Hoz A,  Jin X,  Kreitner K-F,  et al. The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD. BMJ Open Respiratory Research2020;7(1):e000741. [DOI: 10.1136/bmjresp-2020-000741] [PMID: 33268341]">Herth 2020</a>; <a href="./references#CD012066-bbs2-0011" title="NCT03240575. The ENERGITO 2 study compares 2 inhaled medicines for chronic obstructive pulmonary disease (COPD). One medicine is a combination of tiotropium and olodaterol (Stiolto) taken using the Respimat inhaler and the other medicine is a combination of fluticasone and salmeterol taken using the Diskus. ClinicalTrials.gov/show/NCT03240575 (first posted 7 August 2017). ">NCT03240575</a>), two studies used glycopyrronium/formoterol (<a href="./references#CD012066-bbs2-0004" title="Ferguson GT,  Rabe KF,  Martinez FJ,  Fabbri LM,  Wang C,  Ichinose M,  et al . Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respiratory Medicine2018;10:747-58. [DOI: 10.1016/S2213-2600(18)30327-8] [PMID: 30232048]JPRN-JapicCTI-184079. A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort Turbuhaler as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PT010006). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184079. JPRN-JapicCTI-184080. A Randomized, Double-Blind, Parallel-Group, 28-Week, Chronic-Dosing, Multi-Center, Extension Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With Symbicort Turbuhaler as an Active Control (PT010007). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184080. NCT03262012. Study to assess the safety and efficacy of PT010, PT003, and PT009 in Japanese subjects with COPD compared with Symbicort Turbohaler. ClinicalTrials.gov/show/NCT03262012 (first posted 25 August 2017). ">Ferguson 2018</a>; <a href="./references#CD012066-bbs2-0013" title="Rabe KF,  Martinez FJ,  Ferguson GT, Wang C,  Singh D,  Wedzicha JA,  et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New England Journal of Medicine2020;383(1):35-48. [DOI: 10.1056/NEJMoa1916046] [PMID: 32579807]">Rabe 2020</a>), one study used tiotropium/indacaterol (<a href="./references#CD012066-bbs2-0007" title="HoshinoM , OhtawaJ , AkitsuK . Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics2015;30:128-33. [DOI: 10.1016/j.pupt.2014.08.002] [PMID: 25183687]">Hoshino 2015</a>), one study used tiotropium/salmeterol (<a href="./references#CD012066-bbs2-0009" title="MagnussenH , MaltaisF , SchmidtH , KestenS , MetzdorfN . Comparison of tiotropium+salmeterol vs. fluticasone+salmeterol on lung volumes, exercise tolerance and locus of symptom limitation. American Journal of Respiratory and Critical Care Medicine2010;181:A4472. MagnussenH , PaggiaroP , SchmidtH , KestenS , MetzdorfN , MaltaisF . Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respiratory Medicine2012;106(10):1413-20. [DOI: 10.1016/j.rmed.2012.05.011] [PMID: 22749044]">Magnussen 2012</a>), and one study used aclidinium/formoterol (<a href="./references#CD012066-bbs2-0016" title="GreulichT , KostikasK , GagaM , Aalamian-MattheisM , LossiNS , Patalano  F, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. International Journal of Chronic Obstructive Pulmonary Disease2018;13:1229-37. [DOI: 10.2147/COPD.S159732] [PMID: 29713156]VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenA , et al. The efficacy and safety of aclidinium/formoterol fixed-dose combination compared with salmeterol/fluticasone in patients with COPD: results from a phase III study. American Journal of Respiratory and Critical Care Medicine2015;191:A3974. VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenAM , et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal2016;48(4):1030-9. [DOI: 10.1183/13993003.00216-2016] [PMID: 27492833]">Vogelmeier 2016</a>). </p> </section> <section id="CD012066-sec-0048"> <h5 class="title">Outcomes</h5> <p>The reporting of outcomes across studies, organised by the type of LAMA+LABA combination investigated, is shown in <a href="#CD012066-tbl-0003">Table 2</a>. Thirteen studies reported exacerbations in a way that could be brought together in a meta‐analysis, 17 reported serious adverse events, 13 studies reported FEV<sub>1</sub>, 14 reported pneumonia, and 14 reported all‐cause death. Quality of life, as measured by the St. George's Respiratory Questionnaire (SGRQ), was less consistently reported, with nine studies reporting mean total scores and only four reporting the number of participants with a 4‐point or higher improvement on the scale. None of the included studies measured hospitalisations for COPD exacerbations.  </p> <div class="table" id="CD012066-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">ORBIT matrix of outcome reporting across included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign=""> <p><b>Objective or semi‐objective outcomes (investigator‐assessed)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Subjective outcomes (patient‐reported)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Exacerbations</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SAEs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trough FEV<sub>1</sub> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pneumonia</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>All‐cause death</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SGRQ (mean)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SGRQ ≥ 4 unit benefit</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Indacaterol/glycopyrronium studies</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0005" title="Frith PA,  Ashmawi S,  Krishnamurthy S,  Gurgun A,  Hristoskova S,  Pilipovic V,  et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology2018;12:1152-9. [DOI: 10.1111/resp.13374] [PMID: 30074294]"><b>Frith 2018</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0015" title="BatemanE , VogelmeierC , ChenH , BanerjiD . Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study. American College of Chest Physicians2014;145(3):409A. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 demonstrates superior lung function compared to twice-daily salmeterol/fluticasone in all subgroups of COPD patients: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4273. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 improves breathlessness and reduces rescue medication use compared to twice-daily salmeterol/fluticasone in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A2433. MezziK , PallanteJ , AlagappanV , ChenH , BanerjiD . Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β2-agonist/inhaled corticosteroid (LABA/ICS): the ILLUMINATE study. Chest2014;145(3):424A. VogelmeierC , BatemanE , PallanteJ , BryantH , AlagappanVD , AndreaP , et al. Once-daily QVA149 provides superior bronchodilation and improves lung function versus twice-daily fluticasone/salmeterol in COPD patients: the ILLUMINATE study. British Thoracic Society Winter Meeting2012;67:A149, P194. VogelmeierC , BatemanED , PallanteJ , BryantH , AlagappanV , D'Andrea, et al. QVA149 once daily is safe and well tolerated in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1477. VogelmeierCD , BatemanED , D'AndreaP , MezziK , ChenH , BanerjiD , et al. Once-daily QVA149 is more effective than twice-daily salmeterol/fluticasone in improving lung function, in patients with severe chronic obstructive pulmonary disease (COPD): the illuminate study. American Journal of Respiratory and Critical Care Medicine2014;189:A3763. VogelmeierCF , BatemanED , PallanteJ , AlagappanVK , D'AndreaP , ChenH , et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respiratory Medicine2013;1(1):51-60. [DOI: 10.1016/S2213-2600(12)70052-8] [PMID: 24321804]"><b>Vogelmeier 2013</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0017" title="VogelmeierCF , GagaM , Aalamian-MattheisM , GreulichT , MarinJM , CastellaniW , et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research2018;18(1):140. [DOI: 10.1186/s12931-017-0622-x] [PMID: 28720132]"><b>Vogelmeier 2017</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0018" title="KwaijtaalM , WedzichaJ , DecramerM , VestboJ , BanerjiD . Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. Respirology  2014;TP:177. WedzichaJ , VestboJ , GallagherN , BanerjiD . A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study. Chest2014;145(3):408A. WedzichaJA , BanerjiD , ChapmanKR , VestboJ , RocheN , AyersRT , et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. New England Journal of Medicine2016;374(23):2222-34. [DOI: 10.1056/NEJMoa1516385] [PMID: 27181606]"><b>Wedzicha 2016</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0019" title="ZhongN , WangC , ZhouX , ZhangN , HumphriesM , WangL , et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2015;10:1015-26. [DOI: 10.2147/COPD.S84436] [PMID: 26082625]"><b>Zhong 2015</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Umeclidinium/vilanterol studies</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0002" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]"><b>Donohue 2015a</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0003" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]"><b>Donohue 2015b</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0008" title="LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. European Respiratory Journal2018;52:PA4385. [DOI: 10.1183/13993003.congress-2018.PA4385]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. European Respiratory Journal2018;52:PA4384. [DOI: 10.1183/13993003.congress-2018.PA4384]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ . Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. Pneumologie2019;73(Suppl 1):[no pagination]. Lipson DA,  Barnhart F,  Brealey N,  Brooks J,  Criner GJ,  Day NC,  et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine2018;378(18):1671-80. [DOI: 10.1056/NEJMoa1713901] [PMID: 29668352]"><b>Lipson 2018</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0014" title="SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. European Respiratory Journal2014;44(Suppl 58):P290. SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulmonary Medicine2015;15:91. [DOI: 10.1186/s12890-015-0092-1] [PMID: 26286141]"><b>Singh 2015</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Other LAMA/LABA inhaler studies</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0001" title="BeehKM , DeromE , Echave-SustaetaJ , GrönkeL , HamiltonA , ZhaiD , et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study). International Journal of Chronic Obstructive Pulmonary Disease2016;11:193-205. [DOI: 10.2147/COPD.S95055] [PMID: 26893551]DeromE , BeehK , Echave-SustaetaJ , GrönkeL , ZhaiD , BjermerL . Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use. European Respiratory Journal2016;48:PA978. [DOI: 10.1183/13993003.congress-2016]"><b>Beeh 2016</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0004" title="Ferguson GT,  Rabe KF,  Martinez FJ,  Fabbri LM,  Wang C,  Ichinose M,  et al . Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respiratory Medicine2018;10:747-58. [DOI: 10.1016/S2213-2600(18)30327-8] [PMID: 30232048]JPRN-JapicCTI-184079. A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort Turbuhaler as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PT010006). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184079. JPRN-JapicCTI-184080. A Randomized, Double-Blind, Parallel-Group, 28-Week, Chronic-Dosing, Multi-Center, Extension Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With Symbicort Turbuhaler as an Active Control (PT010007). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184080. NCT03262012. Study to assess the safety and efficacy of PT010, PT003, and PT009 in Japanese subjects with COPD compared with Symbicort Turbohaler. ClinicalTrials.gov/show/NCT03262012 (first posted 25 August 2017). "><b>Ferguson 2018</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0006" title="Herth F,  Hohlfeld JM,  Haas J,  Hoz A,  Jin X,  Kreitner K-F,  et al. The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD. BMJ Open Respiratory Research2020;7(1):e000741. [DOI: 10.1136/bmjresp-2020-000741] [PMID: 33268341]"><b>Herth 2020</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0007" title="HoshinoM , OhtawaJ , AkitsuK . Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics2015;30:128-33. [DOI: 10.1016/j.pupt.2014.08.002] [PMID: 25183687]"><b>Hoshino 2015</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0009" title="MagnussenH , MaltaisF , SchmidtH , KestenS , MetzdorfN . Comparison of tiotropium+salmeterol vs. fluticasone+salmeterol on lung volumes, exercise tolerance and locus of symptom limitation. American Journal of Respiratory and Critical Care Medicine2010;181:A4472. MagnussenH , PaggiaroP , SchmidtH , KestenS , MetzdorfN , MaltaisF . Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respiratory Medicine2012;106(10):1413-20. [DOI: 10.1016/j.rmed.2012.05.011] [PMID: 22749044]"><b>Magnussen 2012</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0010" title="Mostafa TM,  El-Azab GA,  Atia GA,  Lotfy NS. The effectiveness of 3 combined therapeutic regimens in Egyptian patients with moderate-to-severe chronic obstructive pulmonary disease: a randomized double-blind prospective pilot study. Current Therapeutic Research Clinical and Experimental2021;94:100625. [DOI: 10.1016/j.curtheres.2021.100625] [PMID: 34306265]"><b>Mostafa 2021</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0011" title="NCT03240575. The ENERGITO 2 study compares 2 inhaled medicines for chronic obstructive pulmonary disease (COPD). One medicine is a combination of tiotropium and olodaterol (Stiolto) taken using the Respimat inhaler and the other medicine is a combination of fluticasone and salmeterol taken using the Diskus. ClinicalTrials.gov/show/NCT03240575 (first posted 7 August 2017). "><b>NCT03240575</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0012" title="RabeKF , TimmerW , SagkriotisA , VielK . Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest2008;134(2):255-62. [DOI: 10.1378/chest.07-2138] [PMID: 18403672]RabeKF , TimmerW , SagriotisA , VielK . Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. In: European Respiratory Society 15th Annual Congress; 2005 Sep 17-20; Copenhagen. 2005. "><b>Rabe 2008</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0013" title="Rabe KF,  Martinez FJ,  Ferguson GT, Wang C,  Singh D,  Wedzicha JA,  et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New England Journal of Medicine2020;383(1):35-48. [DOI: 10.1056/NEJMoa1916046] [PMID: 32579807]"><b>Rabe 2020</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0016" title="GreulichT , KostikasK , GagaM , Aalamian-MattheisM , LossiNS , Patalano  F, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. International Journal of Chronic Obstructive Pulmonary Disease2018;13:1229-37. [DOI: 10.2147/COPD.S159732] [PMID: 29713156]VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenA , et al. The efficacy and safety of aclidinium/formoterol fixed-dose combination compared with salmeterol/fluticasone in patients with COPD: results from a phase III study. American Journal of Respiratory and Critical Care Medicine2015;191:A3974. VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenAM , et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal2016;48(4):1030-9. [DOI: 10.1183/13993003.00216-2016] [PMID: 27492833]"><b>Vogelmeier 2016</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Outcomes shown are those included in the summary of findings table. Outcomes are classed as objective or subjective for the purposes of risk of bias assessment to consider differences in performance and detection bias. </p> <p><b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>ORBIT:</b> outcome reporting bias in trials; <b>SAEs:</b> serious adverse events; <b>SGRQ:</b> St George’s Respiratory Questionnaire </p> </div> </div> </section> </section> <section id="CD012066-sec-0049"> <h4 class="title">Excluded studies</h4> <p>We excluded 24 studies after viewing full texts (see <a href="./references#CD012066-sec-0112" title="">Characteristics of excluded studies</a> and <a href="#CD012066-fig-0001">Figure 1</a>), of which 17 were new excluded studies in this update. Overall, 11 were not relevant because they did not compare LAMA+LABA versus LABA+ICS (<a href="./references#CD012066-bbs2-0022" title="BruhnC . Chronic obstructive pulmonary disease: recommendation of salmeterol in fixed combination. Deutsche Apotheker-Zeitung2003;143(11):48-51. ">Bruhn 2003</a>; <a href="./references#CD012066-bbs2-0023" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (Investigating New Standards for Prophylaxis In Reduction of Exacerbations). In: European Respiratory Society 17th Annual Congress; 2007 Sep 16-18; Stockholm. Vol. 30. 2007:125s P847. ">Calverley 2007</a>; <a href="./references#CD012066-bbs2-0025" title="KnobilK , KalbergC , MerchantK , EmmettA , CicaleM . Maintenance of bronchodilator response for Advair Diskus 250/50 (fluticasone propionate/salmeterol) but not ipratropium/albuterol in patients with COPD. Chest2004;126(Suppl 4):807S. ">Knobil 2004a</a>; <a href="./references#CD012066-bbs2-0026" title="KnobilK , MerchantK , KalbergC , EmmettA , CicaleM . A comparison of patient perceived improvement in symptoms after initiating therapy with either Advair Diskus (fluticasone propionate/salmeterol) 250/50 or ipratropium/albuterol. Chest2004;126(Suppl 4):806S-b-807S-b. ">Knobil 2004b</a>; <a href="./references#CD012066-bbs2-0029" title="NCT00120978. Can advair and flovent reduce systemic inflammation related to chronic obstructive pulmonary disease (COPD)? A multi-center randomized controlled trial. clinicaltrials.gov/ct2/show/NCT00120978 (first received 19 July 2005). ">NCT00120978</a>; <a href="./references#CD012066-bbs2-0040" title="SciurbaFC , KalbergC , EmmettA , MerchantK , BrownC , KnobilK . Efficacy of Advair Diskus 250/50 (fluticasone propionate/salmeterol) or ipratropium/albuterol in patients with COPD associated with chronic bronchitis and/or emphysema. Chest2004;126(Suppl 4):807S-a-808S-a. ">Sciurba 2004</a>; <a href="./references#CD012066-bbs2-0031" title="NCT03504527. Efficiency of budesonide combined with formoterol and tiotropium in the treatment of acute exacerbation of ACO. ClinicalTrials.gov/show/NCT03504527 (first posted 20 April 2018). ">NCT03504527</a>; <a href="./references#CD012066-bbs2-0033" title="NCT04320342. A Phase III Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD. clinicaltrials.gov/show/NCT04320342 (first posted 25 March 2020). ">NCT04320342</a>; <a href="./references#CD012066-bbs2-0034" title="NCT04923347. A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD). clinicaltrials.gov/ct2/show/NCT04923347 (first posted 11 June 2021). ">NCT04923347</a>; <a href="./references#CD012066-bbs2-0035" title="NCT05097014. CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD. clinicaltrials.gov/show/NCT05097014 (first posted 27 October 2021). ">NCT05097014</a>; <a href="./references#CD012066-bbs2-0037" title="PapiA , VestboJ , FabbriL , CorradiM , PrunierH , CohuetG . Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet2018;391(10125):1076-84. [DOI: 10.1016/S0140-6736(18)30206-X] [PMID: 29429593]">Papi 2018</a>), three studies were not eligible because they were systematic reviews (<a href="./references#CD012066-bbs2-0021" title="AzizMIA , TanLE , WuDB , PearceF , ChuaGSW , LinL , et al. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease2018;13:3203-31. ">Aziz 2018</a>; <a href="./references#CD012066-bbs2-0036" title="ObaY , ChandranAV , DevasahayamJV . Long-acting muscarinic antagonist versus inhaled corticosteroid when added to long-acting β-agonist for COPD: a meta-analysis. COPD2016;13(6):677-85. [DOI: 10.3109/15412555.2016.1170799] [PMID: 27148815]">Oba 2016</a>; <a href="./references#CD012066-bbs2-0038" title="PavordID , LettisS , AnzuetoA , BarnesN . Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respiratory Medicine2016;4(9):731-41. [DOI: 10.1016/S2213-2600(16)30148-5] [PMID: 27460163]">Pavord 2016</a>), four studies were not eligible because they did not report an RCT (<a href="./references#CD012066-bbs2-0020" title="AnzuetoAR , VogelmeierCF , KostikasK , MezziK , FucileS , BaderG , et al. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:1325-37. [DOI: 10.2147/COPD.S133307] [PMID: 28496316]">Anzueto 2017</a>; <a href="./references#CD012066-bbs2-0027" title="MahlerDA , KeiningerDL , MezziK , FogelR , BanerjiD . Efficacy of indacaterol/glycopyrronium in patients with COPD who have increased dyspnea with daily activities. Chronic Obstructive Pulmonary Disease2016;3(4):758-68. [DOI: 10.15326/jcopdf.3.4.2016.0138] [PMID: 28848901]">Mahler 2016</a>; <a href="./references#CD012066-bbs2-0030" title="NCT03376295. Comparative effectiveness of COPD treatments. clinicaltrials.gov/show/NCT03376295 (first posted 18 December 2017). ">NCT03376295</a>; <a href="./references#CD012066-bbs2-0032" title="NCT04138758. Comparative effectiveness and safety of tiotropium and olodaterol in comparison to LABA/ICS  [Effectiveness and safety of maintenance treatment with combination of tiotropium and olodaterol in comparison to maintenance treatment with a combination of inhaled corticosteroids and long-acting β2 agonists in COPD patients]. clinicaltrials.gov/ct2/show/NCT04138758 (first posted 30 November 2020). ">NCT04138758</a>), two studies were not eligible because they reported cost‐effectiveness analyses (<a href="./references#CD012066-bbs2-0039" title="PriceD , KeiningerD , Costa-ScharplatzM , MezziK , DimovaM , AsukaiY , et al. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respiratory Medicine2014;108(12):1786-93. ">Price 2014</a>; <a href="./references#CD012066-bbs2-0042" title="SkoupaJ , KasakV , KlimesJ , ValenaT . Indacaterol/glycopyrronium versus salmeterol/fluticasone in patients with COPD. A cost-effectiveness analysis in the Czech Republic. Value in Health Regional Issues2018;16:112-8. [DOI: 10.1016/j.vhri.2018.09.002] [PMID: 30539739]">Skoupa 2018</a>), two studies were letters or commentaries (<a href="./references#CD012066-bbs2-0028" title="MichaelJA , DanaZ . Is combination long-acting beta-agonist and long-acting muscarinic antagonist therapy the future of COPD therapy?Clinical Pulmonary Medicine2016;23(6):288-9. [DOI: 10.1097/CPM.0000000000000181]">Michael 2016</a>; <a href="./references#CD012066-bbs2-0041" title="SinghD , FabbriLM , CorradiM , GeorgesG , GuasconiA , VezzoliS , et al. Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation. European Respiratory Journal2019;53(5):1900235. [DOI: 10.1183/13993003.00235-2019] [PMID: 30792343]">Singh 2019</a>), one study was not eligible because it reported only patients with eosinophilic inflammation (<a href="./references#CD012066-bbs2-0043" title="UMIN000024905. A randomized, open-label, crossover study to evaluate ICS/LABA treatment versus LAMA/LABA treatment in COPD with eosinophilic inflammation. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028656 (first posted 21 November 2016). ">UMIN000024905</a>), and one study was not eligible because the data were only analysed for asthma‐COPD overlap (<a href="./references#CD012066-bbs2-0024" title="EUCTR2015-002046-31-ES. A research study to compare two treatments for treating a respiratory disease known as asthma-COPD overlap syndrome (ACOS) [A randomised, single blind, cross-over study to compare a fixed dose combination of fluticasone propionate / formoterol fumarate (fluticasone /formoterol breath actuated inhaler (BAI)) with a fixed dose combination of indacaterol maleate / glycopyrronium bromide (Ultibro Breezhaler) in subjects with fixed airflow obstruction and elevated eosinophils]. trialsearch.who.int/?TrialID=EUCTR2015-002046-31-ES (first received 3 February 2016). ">EUCTR2015‐002046‐31‐ES</a>). </p> </section> <section id="CD012066-sec-0050"> <h4 class="title">Ongoing studies</h4> <p>We found one ongoing study awaiting results (<a href="./references#CD012066-bbs2-0044" title="EUCTR2016-004473-41-GB. Investigating whether two different COPD inhalers have different effects on chest infections [INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation with Tiotropium and Olodaterol (INCOGNITO trial) - INCOGNITO trial]. trialsearch.who.int/?TrialID=EUCTR2016-004473-41-GB (first received 21 March 2017). ">EUCTR2016‐004473‐41‐GB</a>). The study, which started in 2016, is a trial comparing tiotropium/olodaterol with vilanterol/fluticasone furoate, sponsored by Mundipharma Research Limited (see <a href="./references#CD012066-sec-0113" title="">Characteristics of ongoing studies</a>). The primary end point is change from baseline in eosinophil count and one of the secondary end points is change from baseline in pre‐dose FEV<sub>1</sub>. </p> </section> </section> <section id="CD012066-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>Included studies had generally low risk of bias for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective outcome reporting. The potential for performance and detection bias for different types of outcome (e.g. subjective, objective) is discussed under the Blinding heading. See <a href="#CD012066-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD012066-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: included studies had generally low risk of bias for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective outcome reporting." data-id="CD012066-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: included studies had generally low risk of bias for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective outcome reporting. </p> </div> </div> </div> <section id="CD012066-sec-0052"> <h4 class="title">Allocation</h4> <p>Nine studies reported methods of random sequence generation that suggested a low risk of bias (<a href="./references#CD012066-bbs2-0002" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015a</a>; <a href="./references#CD012066-bbs2-0003" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015b</a>; <a href="./references#CD012066-bbs2-0005" title="Frith PA,  Ashmawi S,  Krishnamurthy S,  Gurgun A,  Hristoskova S,  Pilipovic V,  et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology2018;12:1152-9. [DOI: 10.1111/resp.13374] [PMID: 30074294]">Frith 2018</a>; <a href="./references#CD012066-bbs2-0009" title="MagnussenH , MaltaisF , SchmidtH , KestenS , MetzdorfN . Comparison of tiotropium+salmeterol vs. fluticasone+salmeterol on lung volumes, exercise tolerance and locus of symptom limitation. American Journal of Respiratory and Critical Care Medicine2010;181:A4472. MagnussenH , PaggiaroP , SchmidtH , KestenS , MetzdorfN , MaltaisF . Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respiratory Medicine2012;106(10):1413-20. [DOI: 10.1016/j.rmed.2012.05.011] [PMID: 22749044]">Magnussen 2012</a>; <a href="./references#CD012066-bbs2-0011" title="NCT03240575. The ENERGITO 2 study compares 2 inhaled medicines for chronic obstructive pulmonary disease (COPD). One medicine is a combination of tiotropium and olodaterol (Stiolto) taken using the Respimat inhaler and the other medicine is a combination of fluticasone and salmeterol taken using the Diskus. ClinicalTrials.gov/show/NCT03240575 (first posted 7 August 2017). ">NCT03240575</a>; <a href="./references#CD012066-bbs2-0014" title="SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. European Respiratory Journal2014;44(Suppl 58):P290. SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulmonary Medicine2015;15:91. [DOI: 10.1186/s12890-015-0092-1] [PMID: 26286141]">Singh 2015</a>; <a href="./references#CD012066-bbs2-0015" title="BatemanE , VogelmeierC , ChenH , BanerjiD . Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study. American College of Chest Physicians2014;145(3):409A. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 demonstrates superior lung function compared to twice-daily salmeterol/fluticasone in all subgroups of COPD patients: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4273. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 improves breathlessness and reduces rescue medication use compared to twice-daily salmeterol/fluticasone in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A2433. MezziK , PallanteJ , AlagappanV , ChenH , BanerjiD . Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β2-agonist/inhaled corticosteroid (LABA/ICS): the ILLUMINATE study. Chest2014;145(3):424A. VogelmeierC , BatemanE , PallanteJ , BryantH , AlagappanVD , AndreaP , et al. Once-daily QVA149 provides superior bronchodilation and improves lung function versus twice-daily fluticasone/salmeterol in COPD patients: the ILLUMINATE study. British Thoracic Society Winter Meeting2012;67:A149, P194. VogelmeierC , BatemanED , PallanteJ , BryantH , AlagappanV , D'Andrea, et al. QVA149 once daily is safe and well tolerated in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1477. VogelmeierCD , BatemanED , D'AndreaP , MezziK , ChenH , BanerjiD , et al. Once-daily QVA149 is more effective than twice-daily salmeterol/fluticasone in improving lung function, in patients with severe chronic obstructive pulmonary disease (COPD): the illuminate study. American Journal of Respiratory and Critical Care Medicine2014;189:A3763. VogelmeierCF , BatemanED , PallanteJ , AlagappanVK , D'AndreaP , ChenH , et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respiratory Medicine2013;1(1):51-60. [DOI: 10.1016/S2213-2600(12)70052-8] [PMID: 24321804]">Vogelmeier 2013</a>; <a href="./references#CD012066-bbs2-0018" title="KwaijtaalM , WedzichaJ , DecramerM , VestboJ , BanerjiD . Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. Respirology  2014;TP:177. WedzichaJ , VestboJ , GallagherN , BanerjiD . A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study. Chest2014;145(3):408A. WedzichaJA , BanerjiD , ChapmanKR , VestboJ , RocheN , AyersRT , et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. New England Journal of Medicine2016;374(23):2222-34. [DOI: 10.1056/NEJMoa1516385] [PMID: 27181606]">Wedzicha 2016</a>; <a href="./references#CD012066-bbs2-0019" title="ZhongN , WangC , ZhouX , ZhangN , HumphriesM , WangL , et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2015;10:1015-26. [DOI: 10.2147/COPD.S84436] [PMID: 26082625]">Zhong 2015</a>). Ten studies had an unclear risk of bias in this domain because no details were reported (<a href="./references#CD012066-bbs2-0001" title="BeehKM , DeromE , Echave-SustaetaJ , GrönkeL , HamiltonA , ZhaiD , et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study). International Journal of Chronic Obstructive Pulmonary Disease2016;11:193-205. [DOI: 10.2147/COPD.S95055] [PMID: 26893551]DeromE , BeehK , Echave-SustaetaJ , GrönkeL , ZhaiD , BjermerL . Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use. European Respiratory Journal2016;48:PA978. [DOI: 10.1183/13993003.congress-2016]">Beeh 2016</a>; <a href="./references#CD012066-bbs2-0004" title="Ferguson GT,  Rabe KF,  Martinez FJ,  Fabbri LM,  Wang C,  Ichinose M,  et al . Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respiratory Medicine2018;10:747-58. [DOI: 10.1016/S2213-2600(18)30327-8] [PMID: 30232048]JPRN-JapicCTI-184079. A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort Turbuhaler as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PT010006). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184079. JPRN-JapicCTI-184080. A Randomized, Double-Blind, Parallel-Group, 28-Week, Chronic-Dosing, Multi-Center, Extension Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With Symbicort Turbuhaler as an Active Control (PT010007). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184080. NCT03262012. Study to assess the safety and efficacy of PT010, PT003, and PT009 in Japanese subjects with COPD compared with Symbicort Turbohaler. ClinicalTrials.gov/show/NCT03262012 (first posted 25 August 2017). ">Ferguson 2018</a>; <a href="./references#CD012066-bbs2-0006" title="Herth F,  Hohlfeld JM,  Haas J,  Hoz A,  Jin X,  Kreitner K-F,  et al. The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD. BMJ Open Respiratory Research2020;7(1):e000741. [DOI: 10.1136/bmjresp-2020-000741] [PMID: 33268341]">Herth 2020</a>; <a href="./references#CD012066-bbs2-0007" title="HoshinoM , OhtawaJ , AkitsuK . Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics2015;30:128-33. [DOI: 10.1016/j.pupt.2014.08.002] [PMID: 25183687]">Hoshino 2015</a>; <a href="./references#CD012066-bbs2-0008" title="LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. European Respiratory Journal2018;52:PA4385. [DOI: 10.1183/13993003.congress-2018.PA4385]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. European Respiratory Journal2018;52:PA4384. [DOI: 10.1183/13993003.congress-2018.PA4384]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ . Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. Pneumologie2019;73(Suppl 1):[no pagination]. Lipson DA,  Barnhart F,  Brealey N,  Brooks J,  Criner GJ,  Day NC,  et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine2018;378(18):1671-80. [DOI: 10.1056/NEJMoa1713901] [PMID: 29668352]">Lipson 2018</a>; <a href="./references#CD012066-bbs2-0010" title="Mostafa TM,  El-Azab GA,  Atia GA,  Lotfy NS. The effectiveness of 3 combined therapeutic regimens in Egyptian patients with moderate-to-severe chronic obstructive pulmonary disease: a randomized double-blind prospective pilot study. Current Therapeutic Research Clinical and Experimental2021;94:100625. [DOI: 10.1016/j.curtheres.2021.100625] [PMID: 34306265]">Mostafa 2021</a>; <a href="./references#CD012066-bbs2-0012" title="RabeKF , TimmerW , SagkriotisA , VielK . Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest2008;134(2):255-62. [DOI: 10.1378/chest.07-2138] [PMID: 18403672]RabeKF , TimmerW , SagriotisA , VielK . Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. In: European Respiratory Society 15th Annual Congress; 2005 Sep 17-20; Copenhagen. 2005. ">Rabe 2008</a>; <a href="./references#CD012066-bbs2-0013" title="Rabe KF,  Martinez FJ,  Ferguson GT, Wang C,  Singh D,  Wedzicha JA,  et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New England Journal of Medicine2020;383(1):35-48. [DOI: 10.1056/NEJMoa1916046] [PMID: 32579807]">Rabe 2020</a> <a href="./references#CD012066-bbs2-0016" title="GreulichT , KostikasK , GagaM , Aalamian-MattheisM , LossiNS , Patalano  F, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. International Journal of Chronic Obstructive Pulmonary Disease2018;13:1229-37. [DOI: 10.2147/COPD.S159732] [PMID: 29713156]VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenA , et al. The efficacy and safety of aclidinium/formoterol fixed-dose combination compared with salmeterol/fluticasone in patients with COPD: results from a phase III study. American Journal of Respiratory and Critical Care Medicine2015;191:A3974. VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenAM , et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal2016;48(4):1030-9. [DOI: 10.1183/13993003.00216-2016] [PMID: 27492833]">Vogelmeier 2016</a>; <a href="./references#CD012066-bbs2-0017" title="VogelmeierCF , GagaM , Aalamian-MattheisM , GreulichT , MarinJM , CastellaniW , et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research2018;18(1):140. [DOI: 10.1186/s12931-017-0622-x] [PMID: 28720132]">Vogelmeier 2017</a>). We rated 10 studies at low risk of bias relating to allocation concealment (<a href="./references#CD012066-bbs2-0002" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015a</a>; <a href="./references#CD012066-bbs2-0003" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015b</a>; <a href="./references#CD012066-bbs2-0005" title="Frith PA,  Ashmawi S,  Krishnamurthy S,  Gurgun A,  Hristoskova S,  Pilipovic V,  et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology2018;12:1152-9. [DOI: 10.1111/resp.13374] [PMID: 30074294]">Frith 2018</a>; <a href="./references#CD012066-bbs2-0009" title="MagnussenH , MaltaisF , SchmidtH , KestenS , MetzdorfN . Comparison of tiotropium+salmeterol vs. fluticasone+salmeterol on lung volumes, exercise tolerance and locus of symptom limitation. American Journal of Respiratory and Critical Care Medicine2010;181:A4472. MagnussenH , PaggiaroP , SchmidtH , KestenS , MetzdorfN , MaltaisF . Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respiratory Medicine2012;106(10):1413-20. [DOI: 10.1016/j.rmed.2012.05.011] [PMID: 22749044]">Magnussen 2012</a>; <a href="./references#CD012066-bbs2-0010" title="Mostafa TM,  El-Azab GA,  Atia GA,  Lotfy NS. The effectiveness of 3 combined therapeutic regimens in Egyptian patients with moderate-to-severe chronic obstructive pulmonary disease: a randomized double-blind prospective pilot study. Current Therapeutic Research Clinical and Experimental2021;94:100625. [DOI: 10.1016/j.curtheres.2021.100625] [PMID: 34306265]">Mostafa 2021</a>; <a href="./references#CD012066-bbs2-0011" title="NCT03240575. The ENERGITO 2 study compares 2 inhaled medicines for chronic obstructive pulmonary disease (COPD). One medicine is a combination of tiotropium and olodaterol (Stiolto) taken using the Respimat inhaler and the other medicine is a combination of fluticasone and salmeterol taken using the Diskus. ClinicalTrials.gov/show/NCT03240575 (first posted 7 August 2017). ">NCT03240575</a>; <a href="./references#CD012066-bbs2-0014" title="SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. European Respiratory Journal2014;44(Suppl 58):P290. SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulmonary Medicine2015;15:91. [DOI: 10.1186/s12890-015-0092-1] [PMID: 26286141]">Singh 2015</a>; <a href="./references#CD012066-bbs2-0015" title="BatemanE , VogelmeierC , ChenH , BanerjiD . Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study. American College of Chest Physicians2014;145(3):409A. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 demonstrates superior lung function compared to twice-daily salmeterol/fluticasone in all subgroups of COPD patients: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4273. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 improves breathlessness and reduces rescue medication use compared to twice-daily salmeterol/fluticasone in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A2433. MezziK , PallanteJ , AlagappanV , ChenH , BanerjiD . Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β2-agonist/inhaled corticosteroid (LABA/ICS): the ILLUMINATE study. Chest2014;145(3):424A. VogelmeierC , BatemanE , PallanteJ , BryantH , AlagappanVD , AndreaP , et al. Once-daily QVA149 provides superior bronchodilation and improves lung function versus twice-daily fluticasone/salmeterol in COPD patients: the ILLUMINATE study. British Thoracic Society Winter Meeting2012;67:A149, P194. VogelmeierC , BatemanED , PallanteJ , BryantH , AlagappanV , D'Andrea, et al. QVA149 once daily is safe and well tolerated in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1477. VogelmeierCD , BatemanED , D'AndreaP , MezziK , ChenH , BanerjiD , et al. Once-daily QVA149 is more effective than twice-daily salmeterol/fluticasone in improving lung function, in patients with severe chronic obstructive pulmonary disease (COPD): the illuminate study. American Journal of Respiratory and Critical Care Medicine2014;189:A3763. VogelmeierCF , BatemanED , PallanteJ , AlagappanVK , D'AndreaP , ChenH , et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respiratory Medicine2013;1(1):51-60. [DOI: 10.1016/S2213-2600(12)70052-8] [PMID: 24321804]">Vogelmeier 2013</a>; <a href="./references#CD012066-bbs2-0018" title="KwaijtaalM , WedzichaJ , DecramerM , VestboJ , BanerjiD . Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. Respirology  2014;TP:177. WedzichaJ , VestboJ , GallagherN , BanerjiD . A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study. Chest2014;145(3):408A. WedzichaJA , BanerjiD , ChapmanKR , VestboJ , RocheN , AyersRT , et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. New England Journal of Medicine2016;374(23):2222-34. [DOI: 10.1056/NEJMoa1516385] [PMID: 27181606]">Wedzicha 2016</a>; <a href="./references#CD012066-bbs2-0019" title="ZhongN , WangC , ZhouX , ZhangN , HumphriesM , WangL , et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2015;10:1015-26. [DOI: 10.2147/COPD.S84436] [PMID: 26082625]">Zhong 2015</a>), two at high risk (<a href="./references#CD012066-bbs2-0004" title="Ferguson GT,  Rabe KF,  Martinez FJ,  Fabbri LM,  Wang C,  Ichinose M,  et al . Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respiratory Medicine2018;10:747-58. [DOI: 10.1016/S2213-2600(18)30327-8] [PMID: 30232048]JPRN-JapicCTI-184079. A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort Turbuhaler as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PT010006). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184079. JPRN-JapicCTI-184080. A Randomized, Double-Blind, Parallel-Group, 28-Week, Chronic-Dosing, Multi-Center, Extension Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With Symbicort Turbuhaler as an Active Control (PT010007). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184080. NCT03262012. Study to assess the safety and efficacy of PT010, PT003, and PT009 in Japanese subjects with COPD compared with Symbicort Turbohaler. ClinicalTrials.gov/show/NCT03262012 (first posted 25 August 2017). ">Ferguson 2018</a>; <a href="./references#CD012066-bbs2-0006" title="Herth F,  Hohlfeld JM,  Haas J,  Hoz A,  Jin X,  Kreitner K-F,  et al. The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD. BMJ Open Respiratory Research2020;7(1):e000741. [DOI: 10.1136/bmjresp-2020-000741] [PMID: 33268341]">Herth 2020</a>), and seven as unclear risk of bias because detailed methods were not provided (<a href="./references#CD012066-bbs2-0001" title="BeehKM , DeromE , Echave-SustaetaJ , GrönkeL , HamiltonA , ZhaiD , et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study). International Journal of Chronic Obstructive Pulmonary Disease2016;11:193-205. [DOI: 10.2147/COPD.S95055] [PMID: 26893551]DeromE , BeehK , Echave-SustaetaJ , GrönkeL , ZhaiD , BjermerL . Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use. European Respiratory Journal2016;48:PA978. [DOI: 10.1183/13993003.congress-2016]">Beeh 2016</a>; <a href="./references#CD012066-bbs2-0007" title="HoshinoM , OhtawaJ , AkitsuK . Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics2015;30:128-33. [DOI: 10.1016/j.pupt.2014.08.002] [PMID: 25183687]">Hoshino 2015</a>; <a href="./references#CD012066-bbs2-0008" title="LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. European Respiratory Journal2018;52:PA4385. [DOI: 10.1183/13993003.congress-2018.PA4385]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. European Respiratory Journal2018;52:PA4384. [DOI: 10.1183/13993003.congress-2018.PA4384]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ . Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. Pneumologie2019;73(Suppl 1):[no pagination]. Lipson DA,  Barnhart F,  Brealey N,  Brooks J,  Criner GJ,  Day NC,  et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine2018;378(18):1671-80. [DOI: 10.1056/NEJMoa1713901] [PMID: 29668352]">Lipson 2018</a>; <a href="./references#CD012066-bbs2-0012" title="RabeKF , TimmerW , SagkriotisA , VielK . Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest2008;134(2):255-62. [DOI: 10.1378/chest.07-2138] [PMID: 18403672]RabeKF , TimmerW , SagriotisA , VielK . Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. In: European Respiratory Society 15th Annual Congress; 2005 Sep 17-20; Copenhagen. 2005. ">Rabe 2008</a>; <a href="./references#CD012066-bbs2-0013" title="Rabe KF,  Martinez FJ,  Ferguson GT, Wang C,  Singh D,  Wedzicha JA,  et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New England Journal of Medicine2020;383(1):35-48. [DOI: 10.1056/NEJMoa1916046] [PMID: 32579807]">Rabe 2020</a>; <a href="./references#CD012066-bbs2-0016" title="GreulichT , KostikasK , GagaM , Aalamian-MattheisM , LossiNS , Patalano  F, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. International Journal of Chronic Obstructive Pulmonary Disease2018;13:1229-37. [DOI: 10.2147/COPD.S159732] [PMID: 29713156]VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenA , et al. The efficacy and safety of aclidinium/formoterol fixed-dose combination compared with salmeterol/fluticasone in patients with COPD: results from a phase III study. American Journal of Respiratory and Critical Care Medicine2015;191:A3974. VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenAM , et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal2016;48(4):1030-9. [DOI: 10.1183/13993003.00216-2016] [PMID: 27492833]">Vogelmeier 2016</a>; <a href="./references#CD012066-bbs2-0017" title="VogelmeierCF , GagaM , Aalamian-MattheisM , GreulichT , MarinJM , CastellaniW , et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research2018;18(1):140. [DOI: 10.1186/s12931-017-0622-x] [PMID: 28720132]">Vogelmeier 2017</a>). </p> </section> <section id="CD012066-sec-0053"> <h4 class="title">Blinding</h4> <p>We considered the impact of performance and detection bias on subjective and objective outcomes depending on the blinding methods used within studies. The reporting of objective, semi‐objective, and subjective outcomes across studies is shown in <a href="#CD012066-tbl-0003">Table 2</a>. Though bias is still possible in double‐blind studies for subjective and semi‐objective outcomes where blinding is broken unintentionally, there was no evidence that this had happened. Therefore, we rated all 17 double‐blind studies as low risk of performance and detection bias (<a href="./references#CD012066-bbs2-0001" title="BeehKM , DeromE , Echave-SustaetaJ , GrönkeL , HamiltonA , ZhaiD , et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study). International Journal of Chronic Obstructive Pulmonary Disease2016;11:193-205. [DOI: 10.2147/COPD.S95055] [PMID: 26893551]DeromE , BeehK , Echave-SustaetaJ , GrönkeL , ZhaiD , BjermerL . Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use. European Respiratory Journal2016;48:PA978. [DOI: 10.1183/13993003.congress-2016]">Beeh 2016</a>; <a href="./references#CD012066-bbs2-0002" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015a</a>; <a href="./references#CD012066-bbs2-0003" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015b</a>; <a href="./references#CD012066-bbs2-0005" title="Frith PA,  Ashmawi S,  Krishnamurthy S,  Gurgun A,  Hristoskova S,  Pilipovic V,  et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology2018;12:1152-9. [DOI: 10.1111/resp.13374] [PMID: 30074294]">Frith 2018</a>; <a href="./references#CD012066-bbs2-0004" title="Ferguson GT,  Rabe KF,  Martinez FJ,  Fabbri LM,  Wang C,  Ichinose M,  et al . Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respiratory Medicine2018;10:747-58. [DOI: 10.1016/S2213-2600(18)30327-8] [PMID: 30232048]JPRN-JapicCTI-184079. A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort Turbuhaler as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PT010006). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184079. JPRN-JapicCTI-184080. A Randomized, Double-Blind, Parallel-Group, 28-Week, Chronic-Dosing, Multi-Center, Extension Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With Symbicort Turbuhaler as an Active Control (PT010007). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184080. NCT03262012. Study to assess the safety and efficacy of PT010, PT003, and PT009 in Japanese subjects with COPD compared with Symbicort Turbohaler. ClinicalTrials.gov/show/NCT03262012 (first posted 25 August 2017). ">Ferguson 2018</a>; <a href="./references#CD012066-bbs2-0006" title="Herth F,  Hohlfeld JM,  Haas J,  Hoz A,  Jin X,  Kreitner K-F,  et al. The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD. BMJ Open Respiratory Research2020;7(1):e000741. [DOI: 10.1136/bmjresp-2020-000741] [PMID: 33268341]">Herth 2020</a>; <a href="./references#CD012066-bbs2-0008" title="LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. European Respiratory Journal2018;52:PA4385. [DOI: 10.1183/13993003.congress-2018.PA4385]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. European Respiratory Journal2018;52:PA4384. [DOI: 10.1183/13993003.congress-2018.PA4384]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ . Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. Pneumologie2019;73(Suppl 1):[no pagination]. Lipson DA,  Barnhart F,  Brealey N,  Brooks J,  Criner GJ,  Day NC,  et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine2018;378(18):1671-80. [DOI: 10.1056/NEJMoa1713901] [PMID: 29668352]">Lipson 2018</a>; <a href="./references#CD012066-bbs2-0009" title="MagnussenH , MaltaisF , SchmidtH , KestenS , MetzdorfN . Comparison of tiotropium+salmeterol vs. fluticasone+salmeterol on lung volumes, exercise tolerance and locus of symptom limitation. American Journal of Respiratory and Critical Care Medicine2010;181:A4472. MagnussenH , PaggiaroP , SchmidtH , KestenS , MetzdorfN , MaltaisF . Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respiratory Medicine2012;106(10):1413-20. [DOI: 10.1016/j.rmed.2012.05.011] [PMID: 22749044]">Magnussen 2012</a>; <a href="./references#CD012066-bbs2-0010" title="Mostafa TM,  El-Azab GA,  Atia GA,  Lotfy NS. The effectiveness of 3 combined therapeutic regimens in Egyptian patients with moderate-to-severe chronic obstructive pulmonary disease: a randomized double-blind prospective pilot study. Current Therapeutic Research Clinical and Experimental2021;94:100625. [DOI: 10.1016/j.curtheres.2021.100625] [PMID: 34306265]">Mostafa 2021</a>; <a href="./references#CD012066-bbs2-0011" title="NCT03240575. The ENERGITO 2 study compares 2 inhaled medicines for chronic obstructive pulmonary disease (COPD). One medicine is a combination of tiotropium and olodaterol (Stiolto) taken using the Respimat inhaler and the other medicine is a combination of fluticasone and salmeterol taken using the Diskus. ClinicalTrials.gov/show/NCT03240575 (first posted 7 August 2017). ">NCT03240575</a>; <a href="./references#CD012066-bbs2-0012" title="RabeKF , TimmerW , SagkriotisA , VielK . Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest2008;134(2):255-62. [DOI: 10.1378/chest.07-2138] [PMID: 18403672]RabeKF , TimmerW , SagriotisA , VielK . Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. In: European Respiratory Society 15th Annual Congress; 2005 Sep 17-20; Copenhagen. 2005. ">Rabe 2008</a>; <a href="./references#CD012066-bbs2-0013" title="Rabe KF,  Martinez FJ,  Ferguson GT, Wang C,  Singh D,  Wedzicha JA,  et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New England Journal of Medicine2020;383(1):35-48. [DOI: 10.1056/NEJMoa1916046] [PMID: 32579807]">Rabe 2020</a>; <a href="./references#CD012066-bbs2-0014" title="SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. European Respiratory Journal2014;44(Suppl 58):P290. SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulmonary Medicine2015;15:91. [DOI: 10.1186/s12890-015-0092-1] [PMID: 26286141]">Singh 2015</a>; <a href="./references#CD012066-bbs2-0015" title="BatemanE , VogelmeierC , ChenH , BanerjiD . Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study. American College of Chest Physicians2014;145(3):409A. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 demonstrates superior lung function compared to twice-daily salmeterol/fluticasone in all subgroups of COPD patients: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4273. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 improves breathlessness and reduces rescue medication use compared to twice-daily salmeterol/fluticasone in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A2433. MezziK , PallanteJ , AlagappanV , ChenH , BanerjiD . Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β2-agonist/inhaled corticosteroid (LABA/ICS): the ILLUMINATE study. Chest2014;145(3):424A. VogelmeierC , BatemanE , PallanteJ , BryantH , AlagappanVD , AndreaP , et al. Once-daily QVA149 provides superior bronchodilation and improves lung function versus twice-daily fluticasone/salmeterol in COPD patients: the ILLUMINATE study. British Thoracic Society Winter Meeting2012;67:A149, P194. VogelmeierC , BatemanED , PallanteJ , BryantH , AlagappanV , D'Andrea, et al. QVA149 once daily is safe and well tolerated in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1477. VogelmeierCD , BatemanED , D'AndreaP , MezziK , ChenH , BanerjiD , et al. Once-daily QVA149 is more effective than twice-daily salmeterol/fluticasone in improving lung function, in patients with severe chronic obstructive pulmonary disease (COPD): the illuminate study. American Journal of Respiratory and Critical Care Medicine2014;189:A3763. VogelmeierCF , BatemanED , PallanteJ , AlagappanVK , D'AndreaP , ChenH , et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respiratory Medicine2013;1(1):51-60. [DOI: 10.1016/S2213-2600(12)70052-8] [PMID: 24321804]">Vogelmeier 2013</a>; <a href="./references#CD012066-bbs2-0016" title="GreulichT , KostikasK , GagaM , Aalamian-MattheisM , LossiNS , Patalano  F, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. International Journal of Chronic Obstructive Pulmonary Disease2018;13:1229-37. [DOI: 10.2147/COPD.S159732] [PMID: 29713156]VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenA , et al. The efficacy and safety of aclidinium/formoterol fixed-dose combination compared with salmeterol/fluticasone in patients with COPD: results from a phase III study. American Journal of Respiratory and Critical Care Medicine2015;191:A3974. VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenAM , et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal2016;48(4):1030-9. [DOI: 10.1183/13993003.00216-2016] [PMID: 27492833]">Vogelmeier 2016</a>; <a href="./references#CD012066-bbs2-0018" title="KwaijtaalM , WedzichaJ , DecramerM , VestboJ , BanerjiD . Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. Respirology  2014;TP:177. WedzichaJ , VestboJ , GallagherN , BanerjiD . A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study. Chest2014;145(3):408A. WedzichaJA , BanerjiD , ChapmanKR , VestboJ , RocheN , AyersRT , et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. New England Journal of Medicine2016;374(23):2222-34. [DOI: 10.1056/NEJMoa1516385] [PMID: 27181606]">Wedzicha 2016</a>;<a href="./references#CD012066-bbs2-0019" title="ZhongN , WangC , ZhouX , ZhangN , HumphriesM , WangL , et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2015;10:1015-26. [DOI: 10.2147/COPD.S84436] [PMID: 26082625]">Zhong 2015</a>).  </p> <p>Two studies adopted neither double‐ nor single‐blinding methods and we rated these high risk of bias for both blinding domains, because there is a risk of bias for all outcomes except all‐cause death (<a href="./references#CD012066-bbs2-0007" title="HoshinoM , OhtawaJ , AkitsuK . Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics2015;30:128-33. [DOI: 10.1016/j.pupt.2014.08.002] [PMID: 25183687]">Hoshino 2015</a>; <a href="./references#CD012066-bbs2-0017" title="VogelmeierCF , GagaM , Aalamian-MattheisM , GreulichT , MarinJM , CastellaniW , et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research2018;18(1):140. [DOI: 10.1186/s12931-017-0622-x] [PMID: 28720132]">Vogelmeier 2017</a>). </p> </section> <section id="CD012066-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>Our prespecified criteria for high attrition bias was a dropout rate of more than 20% of randomised participants. Two trials had a dropout rate of more than 20% (<a href="./references#CD012066-bbs2-0010" title="Mostafa TM,  El-Azab GA,  Atia GA,  Lotfy NS. The effectiveness of 3 combined therapeutic regimens in Egyptian patients with moderate-to-severe chronic obstructive pulmonary disease: a randomized double-blind prospective pilot study. Current Therapeutic Research Clinical and Experimental2021;94:100625. [DOI: 10.1016/j.curtheres.2021.100625] [PMID: 34306265]">Mostafa 2021</a>; <a href="./references#CD012066-bbs2-0013" title="Rabe KF,  Martinez FJ,  Ferguson GT, Wang C,  Singh D,  Wedzicha JA,  et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New England Journal of Medicine2020;383(1):35-48. [DOI: 10.1056/NEJMoa1916046] [PMID: 32579807]">Rabe 2020</a>), and we therefore rated them high risk of bias. We considered all other studies to be at low risk of attrition bias.  </p> </section> <section id="CD012066-sec-0055"> <h4 class="title">Selective reporting</h4> <p>Our criteria for rating a study as having a risk of selective reporting bias was if it was a non‐registered trial or if it considerably deviated from the registered protocol concerning outcome reporting. Two trials had a high risk of selective reporting bias due to non‐registration (<a href="./references#CD012066-bbs2-0007" title="HoshinoM , OhtawaJ , AkitsuK . Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics2015;30:128-33. [DOI: 10.1016/j.pupt.2014.08.002] [PMID: 25183687]">Hoshino 2015</a>; <a href="./references#CD012066-bbs2-0010" title="Mostafa TM,  El-Azab GA,  Atia GA,  Lotfy NS. The effectiveness of 3 combined therapeutic regimens in Egyptian patients with moderate-to-severe chronic obstructive pulmonary disease: a randomized double-blind prospective pilot study. Current Therapeutic Research Clinical and Experimental2021;94:100625. [DOI: 10.1016/j.curtheres.2021.100625] [PMID: 34306265]">Mostafa 2021</a>). </p> </section> <section id="CD012066-sec-0056"> <h4 class="title">Other potential sources of bias</h4> <p>Seventeen out of 19 trials were sponsored by pharmaceutical companies (<a href="./references#CD012066-bbs2-0001" title="BeehKM , DeromE , Echave-SustaetaJ , GrönkeL , HamiltonA , ZhaiD , et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study). International Journal of Chronic Obstructive Pulmonary Disease2016;11:193-205. [DOI: 10.2147/COPD.S95055] [PMID: 26893551]DeromE , BeehK , Echave-SustaetaJ , GrönkeL , ZhaiD , BjermerL . Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use. European Respiratory Journal2016;48:PA978. [DOI: 10.1183/13993003.congress-2016]">Beeh 2016</a>; <a href="./references#CD012066-bbs2-0002" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015a</a>; <a href="./references#CD012066-bbs2-0003" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015b</a>; <a href="./references#CD012066-bbs2-0005" title="Frith PA,  Ashmawi S,  Krishnamurthy S,  Gurgun A,  Hristoskova S,  Pilipovic V,  et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology2018;12:1152-9. [DOI: 10.1111/resp.13374] [PMID: 30074294]">Frith 2018</a>; <a href="./references#CD012066-bbs2-0004" title="Ferguson GT,  Rabe KF,  Martinez FJ,  Fabbri LM,  Wang C,  Ichinose M,  et al . Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respiratory Medicine2018;10:747-58. [DOI: 10.1016/S2213-2600(18)30327-8] [PMID: 30232048]JPRN-JapicCTI-184079. A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort Turbuhaler as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PT010006). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184079. JPRN-JapicCTI-184080. A Randomized, Double-Blind, Parallel-Group, 28-Week, Chronic-Dosing, Multi-Center, Extension Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With Symbicort Turbuhaler as an Active Control (PT010007). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184080. NCT03262012. Study to assess the safety and efficacy of PT010, PT003, and PT009 in Japanese subjects with COPD compared with Symbicort Turbohaler. ClinicalTrials.gov/show/NCT03262012 (first posted 25 August 2017). ">Ferguson 2018</a>; <a href="./references#CD012066-bbs2-0006" title="Herth F,  Hohlfeld JM,  Haas J,  Hoz A,  Jin X,  Kreitner K-F,  et al. The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD. BMJ Open Respiratory Research2020;7(1):e000741. [DOI: 10.1136/bmjresp-2020-000741] [PMID: 33268341]">Herth 2020</a>; <a href="./references#CD012066-bbs2-0008" title="LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. European Respiratory Journal2018;52:PA4385. [DOI: 10.1183/13993003.congress-2018.PA4385]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. European Respiratory Journal2018;52:PA4384. [DOI: 10.1183/13993003.congress-2018.PA4384]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ . Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. Pneumologie2019;73(Suppl 1):[no pagination]. Lipson DA,  Barnhart F,  Brealey N,  Brooks J,  Criner GJ,  Day NC,  et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine2018;378(18):1671-80. [DOI: 10.1056/NEJMoa1713901] [PMID: 29668352]">Lipson 2018</a>; <a href="./references#CD012066-bbs2-0009" title="MagnussenH , MaltaisF , SchmidtH , KestenS , MetzdorfN . Comparison of tiotropium+salmeterol vs. fluticasone+salmeterol on lung volumes, exercise tolerance and locus of symptom limitation. American Journal of Respiratory and Critical Care Medicine2010;181:A4472. MagnussenH , PaggiaroP , SchmidtH , KestenS , MetzdorfN , MaltaisF . Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respiratory Medicine2012;106(10):1413-20. [DOI: 10.1016/j.rmed.2012.05.011] [PMID: 22749044]">Magnussen 2012</a>; <a href="./references#CD012066-bbs2-0011" title="NCT03240575. The ENERGITO 2 study compares 2 inhaled medicines for chronic obstructive pulmonary disease (COPD). One medicine is a combination of tiotropium and olodaterol (Stiolto) taken using the Respimat inhaler and the other medicine is a combination of fluticasone and salmeterol taken using the Diskus. ClinicalTrials.gov/show/NCT03240575 (first posted 7 August 2017). ">NCT03240575</a>; <a href="./references#CD012066-bbs2-0012" title="RabeKF , TimmerW , SagkriotisA , VielK . Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest2008;134(2):255-62. [DOI: 10.1378/chest.07-2138] [PMID: 18403672]RabeKF , TimmerW , SagriotisA , VielK . Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. In: European Respiratory Society 15th Annual Congress; 2005 Sep 17-20; Copenhagen. 2005. ">Rabe 2008</a>; <a href="./references#CD012066-bbs2-0013" title="Rabe KF,  Martinez FJ,  Ferguson GT, Wang C,  Singh D,  Wedzicha JA,  et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New England Journal of Medicine2020;383(1):35-48. [DOI: 10.1056/NEJMoa1916046] [PMID: 32579807]">Rabe 2020</a>; <a href="./references#CD012066-bbs2-0014" title="SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. European Respiratory Journal2014;44(Suppl 58):P290. SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulmonary Medicine2015;15:91. [DOI: 10.1186/s12890-015-0092-1] [PMID: 26286141]">Singh 2015</a>; <a href="./references#CD012066-bbs2-0015" title="BatemanE , VogelmeierC , ChenH , BanerjiD . Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study. American College of Chest Physicians2014;145(3):409A. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 demonstrates superior lung function compared to twice-daily salmeterol/fluticasone in all subgroups of COPD patients: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4273. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 improves breathlessness and reduces rescue medication use compared to twice-daily salmeterol/fluticasone in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A2433. MezziK , PallanteJ , AlagappanV , ChenH , BanerjiD . Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β2-agonist/inhaled corticosteroid (LABA/ICS): the ILLUMINATE study. Chest2014;145(3):424A. VogelmeierC , BatemanE , PallanteJ , BryantH , AlagappanVD , AndreaP , et al. Once-daily QVA149 provides superior bronchodilation and improves lung function versus twice-daily fluticasone/salmeterol in COPD patients: the ILLUMINATE study. British Thoracic Society Winter Meeting2012;67:A149, P194. VogelmeierC , BatemanED , PallanteJ , BryantH , AlagappanV , D'Andrea, et al. QVA149 once daily is safe and well tolerated in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1477. VogelmeierCD , BatemanED , D'AndreaP , MezziK , ChenH , BanerjiD , et al. Once-daily QVA149 is more effective than twice-daily salmeterol/fluticasone in improving lung function, in patients with severe chronic obstructive pulmonary disease (COPD): the illuminate study. American Journal of Respiratory and Critical Care Medicine2014;189:A3763. VogelmeierCF , BatemanED , PallanteJ , AlagappanVK , D'AndreaP , ChenH , et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respiratory Medicine2013;1(1):51-60. [DOI: 10.1016/S2213-2600(12)70052-8] [PMID: 24321804]">Vogelmeier 2013</a>; <a href="./references#CD012066-bbs2-0016" title="GreulichT , KostikasK , GagaM , Aalamian-MattheisM , LossiNS , Patalano  F, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. International Journal of Chronic Obstructive Pulmonary Disease2018;13:1229-37. [DOI: 10.2147/COPD.S159732] [PMID: 29713156]VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenA , et al. The efficacy and safety of aclidinium/formoterol fixed-dose combination compared with salmeterol/fluticasone in patients with COPD: results from a phase III study. American Journal of Respiratory and Critical Care Medicine2015;191:A3974. VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenAM , et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal2016;48(4):1030-9. [DOI: 10.1183/13993003.00216-2016] [PMID: 27492833]">Vogelmeier 2016</a>; <a href="./references#CD012066-bbs2-0017" title="VogelmeierCF , GagaM , Aalamian-MattheisM , GreulichT , MarinJM , CastellaniW , et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research2018;18(1):140. [DOI: 10.1186/s12931-017-0622-x] [PMID: 28720132]">Vogelmeier 2017</a>; <a href="./references#CD012066-bbs2-0018" title="KwaijtaalM , WedzichaJ , DecramerM , VestboJ , BanerjiD . Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. Respirology  2014;TP:177. WedzichaJ , VestboJ , GallagherN , BanerjiD . A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study. Chest2014;145(3):408A. WedzichaJA , BanerjiD , ChapmanKR , VestboJ , RocheN , AyersRT , et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. New England Journal of Medicine2016;374(23):2222-34. [DOI: 10.1056/NEJMoa1516385] [PMID: 27181606]">Wedzicha 2016</a>; <a href="./references#CD012066-bbs2-0019" title="ZhongN , WangC , ZhouX , ZhangN , HumphriesM , WangL , et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2015;10:1015-26. [DOI: 10.2147/COPD.S84436] [PMID: 26082625]">Zhong 2015</a>). Although pharmaceutical company sponsorship does not automatically signify a high risk of bias, scrutiny of disclosure statements revealed that all 17 studies had authors that were employed by the company, held shares, and/or received grants or fees for the work. In all cases, these authors were involved explicitly in the design of the study, its conduct (including data analysis), or interpretation and write up, which warranted high risk of bias judgements.  </p> <p>We found no other sources of bias apart from conflicts of interest. </p> </section> </section> <section id="CD012066-sec-0057"> <h3 class="title" id="CD012066-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD012066-tbl-0001"><b>Summary of findings 1</b> Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)</a> </p> <p>See <a href="./full#CD012066-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD012066-sec-0058"> <h4 class="title">Primary outcomes</h4> <section id="CD012066-sec-0059"> <h5 class="title">Exacerbations (participants with one or more event)</h5> <p>Thirteen studies with 20,960 participants evaluated exacerbations over six to 52 weeks of observation. Participants randomised to LAMA+LABA had similar odds of experiencing one or more exacerbations to those randomised to LABA+ICS (OR 0.91, 95% CI 0.78 to 1.06; P = 0.22, I<sup>2</sup> = 56%;  moderate‐certainty evidence; <a href="./references#CD012066-fig-0003" title="">Analysis 1.1</a>). Our confidence in the result was reduced from high to moderate due to considerable heterogeneity. </p> <p>The test for subgroup differences indicated a difference between LAMA+LABA subgroups, with the largest benefit of LAMA+LABA versus LABA+ICS seen in the glycopyrronium/indacaterol studies (OR 0.72, 95% CI 0.63 to 0.83; P = 0.02, I<sup>2</sup> = 0%) and the pooled effect for the umeclidinium/vilanterol subgroup laying in the opposite direction (OR 1.20, 95% CI 1.03 to 1.40; P &lt; 0.001, I<sup>2</sup> = 0%; test for subgroup differences P &lt; 0.001). However, results are observational and should be interpreted with caution. The overall pooled result was similar to the random‐effects analysis when a fixed‐effect model was tested (OR 0.94, 95% CI 0.87 to 1.01; P = 0.08, I<sup>2</sup> = 56%; <a href="./references#CD012066-fig-0010" title="">Analysis 1.8</a>). </p> </section> <section id="CD012066-sec-0060"> <h5 class="title">Serious adverse events (participants with one or more event)</h5> <p>Eighteen studies with 23,183 participants evaluated serious adverse events over six to 52 weeks of observation. We discarded data from one study because no serious adverse events were reported in either arm (<a href="./references#CD012066-bbs2-0006" title="Herth F,  Hohlfeld JM,  Haas J,  Hoz A,  Jin X,  Kreitner K-F,  et al. The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD. BMJ Open Respiratory Research2020;7(1):e000741. [DOI: 10.1136/bmjresp-2020-000741] [PMID: 33268341]">Herth 2020</a>). Participants randomised to LAMA+LABA had similar odds of having a serious adverse event as those randomised to LABA+ICS (OR 1.02, 95% CI 0.91 to 1.15; I<sup>2</sup> = 20%; high‐certainty evidence; <a href="./references#CD012066-fig-0004" title="">Analysis 1.2</a>; test for subgroup differences P = 0.25). We did not downgrade the evidence in any of the GRADE domains and therefore have high confidence in the result. </p> <p>Results were similar to the random‐effects analysis when a fixed‐effect model was tested (OR 1.03, 95% CI 0.95 to 1.12; I<sup>2</sup> = 20%; <a href="./references#CD012066-fig-0011" title="">Analysis 1.9</a>).  </p> </section> <section id="CD012066-sec-0061"> <h5 class="title">Quality of life, as measured by the St. George's Respiratory Questionnaire (SGRQ) total score change from baseline </h5> <p>Nine studies with 14,437 participants assessed mean change in SGRQ scores over 12 to 52 weeks of observation. The benefit of LAMA+LABA versus LAMA+ICS was neither statistically nor clinically important (MD ‐0.57, 95% CI ‐1.36 to 0.21; I<sup>2</sup> = 78%; moderate‐certainty evidence; <a href="./references#CD012066-fig-0005" title="">Analysis 1.3</a>; test for subgroup differences P &lt; 0.004). Our confidence in the result was reduced from high to moderate due to considerable heterogeneity.  </p> <p>The test for subgroup differences indicated a difference between LAMA+LABA subgroups, with the largest benefit of LAMA+LABA versus LABA+ICS seen in the indacaterol/glycopyrronium studies (MD ‐1.29, 95% CI ‐2.08 to ‐0.50; P = 0.001, I<sup>2</sup> = 0%). The sensitivity analysis using a fixed‐effect model brought the point estimate from lying in favour of LAMA+LABA to zero (i.e. no effect) (MD 0.00, 95% CI ‐0.02 to 0.02; I<sup>2</sup> = 78%; <a href="./references#CD012066-fig-0012" title="">Analysis 1.10</a>).  </p> </section> <section id="CD012066-sec-0062"> <h5 class="title">Trough FEV<sub>1</sub> mean change </h5> <p>In total, 12 studies with 14,681 participants reported change in trough FEV<sub>1</sub> over six to 52 weeks. Compared to LABA+ICS, there was a significant increase in the trough FEV<sub>1</sub> change from baseline with LAMA+LABA (MD 0.07 L, 95% CI 0.05 to 0.08; I<sup>2</sup> = 73%; moderate‐certainty evidence; <a href="./references#CD012066-fig-0006" title="">Analysis 1.4</a>). This difference was less than the minimal clinically important difference (<a href="./references#CD012066-bbs2-0049" title="DonohueJF . Minimal clinically important differences in COPD lung function. COPD2005;2(1):111-24. [DOI: 10.1081/copd-200053377] [PMID: 17136971]">Donohue 2005</a>). Our confidence in the result was reduced from high to moderate due to considerable heterogeneity. </p> <p>In the LAMA+LABA subgroup analysis, each subgroup was consistently associated with an increase in trough FEV<sub>1</sub> change from baseline (test for subgroup differences P = 0.93). Results from the sensitivity analysis using a fixed‐effect model were in line with the main random‐effects analysis (MD 0.06, 95% CI 0.05 to 0.07; I<sup>2</sup> = 73%; <a href="./references#CD012066-fig-0013" title="">Analysis 1.11</a>). </p> </section> </section> <section id="CD012066-sec-0063"> <h4 class="title">Secondary outcomes</h4> <section id="CD012066-sec-0064"> <h5 class="title">Pneumonia (participants with one or more event)</h5> <p>Fourteen studies with 21,829 participants evaluated pneumonia over 12 to 52 weeks of observation. Compared to LABA+ICS, there was a large reduction in the number of participants experiencing one or more episodes of pneumonia with LAMA+LABA (OR 0.61, 95% CI 0.52 to 0.72; I<sup>2</sup> = 0%; high‐certainty evidence; <a href="./references#CD012066-fig-0007" title="">Analysis 1.5</a>; test for subgroup differences P = 0.90). We did not downgrade the evidence in any of the GRADE domains and therefore have high confidence in the result. Although it would be possible to calculate an absolute risk reduction, we decided not to do so, as the absolute effect size is highly dependent on the study duration. </p> </section> <section id="CD012066-sec-0065"> <h5 class="title">All‐cause death</h5> <p>Fifteen studies with 21,510 participants evaluated all‐cause death at six to 52 weeks of observation. There was an increased risk of all‐cause death with LAMA+LABA compared with LABA+ICS (OR 1.35, 95% CI 1.05 to 1.75; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD012066-fig-0008" title="">Analysis 1.6</a>). Our confidence in the result was reduced from high to moderate due to imprecision in the effect. </p> <p>Point estimates and confidence intervals varied across subgroups containing studies of different LAMA+LABA combinations, but the test for subgroup differences indicated the differences were not statistically significant (test for subgroup differences P = 0.51). </p> </section> <section id="CD012066-sec-0066"> <h5 class="title">SGRQ improvement of 4 points or greater</h5> <p>Four studies with 13,614 participants evaluated the SGRQ total score change from baseline (≥ 4 points) at 26 to 52 weeks of observation. There was little to no significant change in the SGRQ total score (4 points or greater) between LAMA+LABA and LABA+ICS (OR 1.06, 95% CI 0.90 to 1.25; I<sup>2</sup> = 77%; moderate‐certainty evidence; <a href="./references#CD012066-fig-0009" title="">Analysis 1.7</a>; test for subgroup differences P = 0.002). Our confidence in the result was reduced from high to moderate due to considerable heterogeneity. </p> </section> <section id="CD012066-sec-0067"> <h5 class="title">Hospitalisations for COPD exacerbations</h5> <p>None of the included studies reported this outcome.  </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012066-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012066-sec-0068"></div> <section id="CD012066-sec-0069"> <h3 class="title" id="CD012066-sec-0069">Summary of main results</h3> <p>We conducted a systematic review and meta‐analysis to compare the efficacy and safety of LAMA+LABA and LABA+ICS therapy in people with stable COPD. The review includes 19 studies with 22,354 participants, including 11 studies from the previous version of the review. Most studies were parallel, double‐blind RCTs. We noted selection, attrition, and selective reporting bias in a small number of studies and there is a risk of bias from involvement of authors employed by the pharmaceutical sponsors in 17 of the 19 studies.  </p> <p>Compared to LABA+ICS, the review found there to be a greater improvement in FEV<sub>1</sub> in the LAMA+LABA group (moderate‐certainty evidence), lower odds of pneumonia (high‐certainty evidence), and increased mortality (moderate‐certainty evidence). This update did not find a difference in exacerbations between LAMA+LABA and LABA+ICS (moderate‐certainty evidence), which was reported in the previous review (<a href="./references#CD012066-bbs2-0077" title="HoritaN , GotoA , ShibataY , OtaE , NakashimaK , NagaiK , KanekoT . Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD012066. [DOI: 10.1002/14651858.CD012066.pub2]">Horita 2017</a>). The odds of having a serious adverse event are likely to be similar for LAMA+LABA and LABA+ICS (high‐certainty evidence), as were quality of life scores as measured by the St George's Respiratory Questionnaire (moderate‐certainty evidence).  </p> </section> <section id="CD012066-sec-0070"> <h3 class="title" id="CD012066-sec-0070">Overall completeness and applicability of evidence</h3> <p>Most of the studies included in this analysis recruited people with moderate to severe COPD, according to the GOLD reports. Therefore, attention should be paid when applying our results to people with mild and very severe COPD. </p> <p>Despite the apparent benefits of LAMA+LABA over LABA+ICS for trough FEV<sub>1</sub> and reduced risk of pneumonia, the findings suggest little difference for exacerbations, serious adverse events, and quality of life as measured by the SGRQ. Although exacerbations and pneumonia should share risk factors, a paradox can occur in COPD treated with ICS where the risk of exacerbations and mortality reduces despite an increased risk of pneumonia. The apparent conflicting results of this review may partially relate to this relationship, and should also be interpreted with caution due to the limited follow‐up and number of observed events. It should also be noted that studies recruited outpatient populations and cases of pneumonia may have been mild. Variation in study results also reduced our confidence in some of these findings, and in some cases, such as the exacerbations analysis where <a href="./references#CD012066-bbs2-0008" title="LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. European Respiratory Journal2018;52:PA4385. [DOI: 10.1183/13993003.congress-2018.PA4385]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. European Respiratory Journal2018;52:PA4384. [DOI: 10.1183/13993003.congress-2018.PA4384]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ . Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. Pneumologie2019;73(Suppl 1):[no pagination]. Lipson DA,  Barnhart F,  Brealey N,  Brooks J,  Criner GJ,  Day NC,  et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine2018;378(18):1671-80. [DOI: 10.1056/NEJMoa1713901] [PMID: 29668352]">Lipson 2018</a> reported a significant benefit in favour of LABA+ICS, outlier studies impacted on the overall findings. </p> <p>There was also variation across the included studies in their exclusion of people with a history of asthma, and the reporting of blood eosinophil counts that may be indicative of ACOS was patchy. Given that ICSs are effective in preventing exacerbations in asthma (<a href="./references#CD012066-bbs2-0068" title="Reddel HK,  Bacharier LB,  Bateman ED,  Brightling CE,  Brusselle GG,  Buhl R,  et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. European Respiratory Journal2021;59(1):2102730. [DOI: 10.1183/13993003.02730-2021] [PMID: 34667060]">Reddel 2021</a>), results may have been skewed in favour of the LABA+ICS group because people with ACOS or a high blood eosinophil sensitivity to ICS may have fared better than those receiving LAMA+LABA. </p> <p>Studies further varied in their inclusion criteria around recent history of exacerbation, which is a known risk factor for COPD mortality (<a href="./references#CD012066-bbs2-0051" title="EstebanC , Castro-Acosta A,  Alvarez-Martínez CJ,  Capelastegui A, López-Campos JL,  Pozo-Rodriguez F. Predictors of one-year mortality after hospitalization for an exacerbation of COPD. BMC Pulmonary Medicine2018;18(1):18. [DOI: 10.1186/s12890-018-0574-z] [PMID: 29370849]">Esteban 2018</a>). The variation may have impacted on analyses where studies that enroled participants with a history of exacerbations carried a large proportion of the weight within an analysis (e.g. <a href="./references#CD012066-bbs2-0013" title="Rabe KF,  Martinez FJ,  Ferguson GT, Wang C,  Singh D,  Wedzicha JA,  et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New England Journal of Medicine2020;383(1):35-48. [DOI: 10.1056/NEJMoa1916046] [PMID: 32579807]">Rabe 2020</a> in the all‐cause death analysis). Moreover, the % predicted FEV<sub>1</sub> of participants in <a href="./references#CD012066-bbs2-0013" title="Rabe KF,  Martinez FJ,  Ferguson GT, Wang C,  Singh D,  Wedzicha JA,  et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New England Journal of Medicine2020;383(1):35-48. [DOI: 10.1056/NEJMoa1916046] [PMID: 32579807]">Rabe 2020</a> was as low as 25% to 65%, suggesting that participants' condition in this trial was poorer than those in other RCTs.  </p> <p>Limitations of the evidence include the lack of long‐term follow‐up data and the possibility that discontinuation of therapy may have contributed to early events such as withdrawal and death. For example, in <a href="./references#CD012066-bbs2-0018" title="KwaijtaalM , WedzichaJ , DecramerM , VestboJ , BanerjiD . Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. Respirology  2014;TP:177. WedzichaJ , VestboJ , GallagherN , BanerjiD . A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study. Chest2014;145(3):408A. WedzichaJA , BanerjiD , ChapmanKR , VestboJ , RocheN , AyersRT , et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. New England Journal of Medicine2016;374(23):2222-34. [DOI: 10.1056/NEJMoa1516385] [PMID: 27181606]">Wedzicha 2016</a>, all participants were treated with tiotropium during a one‐month run‐in period. Exacerbations in the LAMA+LABA groups might have occurred because participants who had been using ICSs prior to the trial had to discontinue them. As such, in studies where a recent exacerbation was not permitted, removal of these participants may have led to a biased population. In <a href="./references#CD012066-bbs2-0008" title="LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. European Respiratory Journal2018;52:PA4385. [DOI: 10.1183/13993003.congress-2018.PA4385]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. European Respiratory Journal2018;52:PA4384. [DOI: 10.1183/13993003.congress-2018.PA4384]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ . Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. Pneumologie2019;73(Suppl 1):[no pagination]. Lipson DA,  Barnhart F,  Brealey N,  Brooks J,  Criner GJ,  Day NC,  et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine2018;378(18):1671-80. [DOI: 10.1056/NEJMoa1713901] [PMID: 29668352]">Lipson 2018</a>, the participants who had been receiving ICSs before enroling in the trial were partly randomised to the LAMA+LABA group. These participants were actually stepping down in their treatment; this could lead to COPD exacerbations (<a href="./references#CD012066-bbs2-0072" title="SuissaS , DrazenJM . Making sense of triple inhaled therapy for COPD. New England Journal of Medicine2018;378(18):1723-4. [DOI: 10.1056/NEJMe1716802.] [PMID: 29669218]">Suissa 2018</a>).  </p> </section> <section id="CD012066-sec-0071"> <h3 class="title" id="CD012066-sec-0071">Certainty of the evidence</h3> <p>GRADE ratings of certainty in the evidence along with reasons for downgrading, or choosing not to downgrade, are summarised in <a href="./full#CD012066-tbl-0001">summary of findings Table 1</a>. We downgraded most outcomes once to moderate certainty, meaning the true effect is likely to be close to the estimate of effect but may be substantially different. The pooled effects for serious adverse events and pneumonia were both rated high certainty, meaning the true effect lies close to that of the estimate of effect. The most common reason for downgrading was considerable heterogeneity (exacerbations, SGRQ mean change, FEV<sub>1</sub> mean change and SGRQ improvement of 4 or more points), which may reflect the clinical heterogeneity between studies, discussed above. Only the all‐cause death analysis was downgraded due to imprecision, because there was a very small number of events in the analysis, leading to wide confidence intervals. The confidence intervals around the pooled result for several other outcomes include a potential benefit in either direction (exacerbations, serious adverse events, SGRQ mean change, SGRQ improvement of 4 or more points), but they lay within the threshold for clinical importance that was predefined in the protocol for this review, so we chose not to downgrade (0.7 to 1.5 for OR outcomes; 4‐point MCID for SGRQ). </p> <p>We did not downgrade any outcomes due to indirectness of the contributing studies to the review question. However, variation in study inclusion criteria around recent history of exacerbation, baseline percentage predicted FEV<sub>1</sub>, and exclusion of asthma are noteworthy, and affect how the pooled results can be interpreted and applied to different subpopulations of people with COPD. Similarly, we did not downgrade any outcomes for suspected publication bias, and there was no obvious asymmetry on funnel plots for the primary outcomes. </p> <p>The potential impact of risk of bias across analyses is difficult to quantify, and we did not prespecify a threshold for downgrading the evidence due to risk of bias in certain domains or in studies contributing a certain percentage of the analysis weight. Amongst the 19 included studies, only two with a few participants did not have any commercial sponsorship (<a href="./references#CD012066-bbs2-0007" title="HoshinoM , OhtawaJ , AkitsuK . Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics2015;30:128-33. [DOI: 10.1016/j.pupt.2014.08.002] [PMID: 25183687]">Hoshino 2015</a>; <a href="./references#CD012066-bbs2-0010" title="Mostafa TM,  El-Azab GA,  Atia GA,  Lotfy NS. The effectiveness of 3 combined therapeutic regimens in Egyptian patients with moderate-to-severe chronic obstructive pulmonary disease: a randomized double-blind prospective pilot study. Current Therapeutic Research Clinical and Experimental2021;94:100625. [DOI: 10.1016/j.curtheres.2021.100625] [PMID: 34306265]">Mostafa 2021</a>). In the remaining 17 studies, study authors involved in key aspects of the study were employed by, held shares for, or received fees from the sponsoring manufacturer (<a href="#CD012066-tbl-0004">Table 3</a>). Otherwise, the included studies were mostly well‐designed and conducted, with adequate sample sizes. Therefore, across outcomes, all or almost all studies are at high risk of 'other' bias due to conflicts of interest, and studies contributing between 18.5% and 35.9% of the analysis weight are rated high risk of bias in at least one other domain. We set a post hoc rule for downgrading, and considered it insufficient to downgrade if studies contributing more than half the analysis weight were at low or unclear risk of bias in all but the 'other' domain, meaning no outcomes were downgraded for this reason. There is a need for large, well‐conducted trials funded by national funding bodies to overcome the bias inherent in evidence funded by pharmaceutical companies. </p> <div class="table" id="CD012066-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sponsor list for chronic obstructive pulmonary disease studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sponsor</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Record count</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% of 1723</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GlaxoSmithKline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Novartis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AstraZeneca</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Boehringer Ingelheim</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pfizer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nycomed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.84</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chiesi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Almirall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.09</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Merck</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.74</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Web of Science Core Collection, advanced search for "TI=(COPD) AND TS=(inhal*)" without any restriction hit 1723 reports as of 13 June 2016. "Results analysis" &gt; "Source Titles" output the table above. </p> </div> </div> </section> <section id="CD012066-sec-0072"> <h3 class="title" id="CD012066-sec-0072">Potential biases in the review process</h3> <p>Although we tried to extract data on exacerbations of any severity, some trials counted only moderate to severe exacerbations. In addition, some outcomes, such as exacerbation and adverse effects, were dependent on the threshold determined by the researchers of the original articles. Confidence intervals for the two cross‐over studies might be conservative in our analysis (<a href="./references#CD012066-bbs2-0009" title="MagnussenH , MaltaisF , SchmidtH , KestenS , MetzdorfN . Comparison of tiotropium+salmeterol vs. fluticasone+salmeterol on lung volumes, exercise tolerance and locus of symptom limitation. American Journal of Respiratory and Critical Care Medicine2010;181:A4472. MagnussenH , PaggiaroP , SchmidtH , KestenS , MetzdorfN , MaltaisF . Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respiratory Medicine2012;106(10):1413-20. [DOI: 10.1016/j.rmed.2012.05.011] [PMID: 22749044]">Magnussen 2012</a>; <a href="./references#CD012066-bbs2-0017" title="VogelmeierCF , GagaM , Aalamian-MattheisM , GreulichT , MarinJM , CastellaniW , et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research2018;18(1):140. [DOI: 10.1186/s12931-017-0622-x] [PMID: 28720132]">Vogelmeier 2017</a>), due to the way we included the data in the analysis to avoid overestimating precision. </p> </section> <section id="CD012066-sec-0073"> <h3 class="title" id="CD012066-sec-0073">Agreements and disagreements with other studies or reviews</h3> <p>The previous version of this review, which included 11 studies with 9839 participants (<a href="./references#CD012066-bbs2-0077" title="HoritaN , GotoA , ShibataY , OtaE , NakashimaK , NagaiK , KanekoT . Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD012066. [DOI: 10.1002/14651858.CD012066.pub2]">Horita 2017</a>), concluded there was no difference between the LAMA+LABA and LABA+ICS groups for all‐cause death (OR 1.01, 95% CI 0.61 to 1.67), whereas this update found a probable benefit of LABA+ICS over LAMA+LABA. As discussed above, this may be partially explained by differences in the presence and reporting of ACOS within the newer studies that carry a large proportion of the analysis weight.  </p> <p>A recent network meta‐analysis which included a LAMA+LABA versus LABA+ICS comparison looked at many of the same outcomes to this review in studies of low‐ and high‐risk COPD populations (<a href="./references#CD012066-bbs2-0065" title="ObaY , KeeneyE , GhatehordeN , DiasS . Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews2018, Issue 12. Art. No: CD012620. [DOI: 10.1002/14651858.CD012620.pub2] [PMID: 30521694]">Oba 2018</a>). The review included many of the same studies (nine studies), and many others for comparisons not of interest to this review, but excluded those with a cross‐over design and those shorter than 12 weeks. Oba and colleagues also presented data separately for high‐ and low‐risk populations and looked at FEV<sub>1</sub> and the SGRQ at three, six, and 12 months. Results for the high‐risk population are largely in line with this review: the finding relating to exacerbations was similar to ours (OR 0.89, 95% CI 0.78 to 1.04) and quality of life, as measured by the SGRQ (MD ‐1.47, 95% CI ‐3.74 to 0.45). It is noteworthy that there was no significant difference in all‐cause mortality (OR 1.15, 95% CI 0.70 to 1.95). A similarly large effect was seen for pneumonia (OR 0.61, 95% CI 0.34 to 1.01) and trough FEV<sub>1</sub> (MD 0.05, 95% CI 0.03 to 0.07) in favour of LAMA+LABA, and effects were generally smaller or inconclusive in the low‐risk population studies (<a href="./references#CD012066-bbs2-0065" title="ObaY , KeeneyE , GhatehordeN , DiasS . Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews2018, Issue 12. Art. No: CD012620. [DOI: 10.1002/14651858.CD012620.pub2] [PMID: 30521694]">Oba 2018</a>). A further review of incident pneumonia and mortality in people with COPD showed no difference between ICS and non‐ICS arms in pneumonia‐related mortality despite a significantly increased risk of pneumonia (<a href="./references#CD012066-bbs2-0052" title="Festic E,  ScanlonPD . Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?American Journal of Respiratory and Critical Care Medicine2015;191(2):141-8. [DOI: 10.1164/rccm.201409-1654PP] [PMID: 25409118]">Festic 2015</a>).  </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012066-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/urn:x-wiley:14651858:media:CD012066:CD012066-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram" data-id="CD012066-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_t/tCD012066-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full#CD012066-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012066-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/urn:x-wiley:14651858:media:CD012066:CD012066-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: included studies had generally low risk of bias for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective outcome reporting." data-id="CD012066-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_t/tCD012066-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: included studies had generally low risk of bias for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective outcome reporting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full#CD012066-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012066-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/urn:x-wiley:14651858:media:CD012066:CD012066-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 1: Exacerbations" data-id="CD012066-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_t/tCD012066-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 1: Exacerbations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/references#CD012066-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012066-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/urn:x-wiley:14651858:media:CD012066:CD012066-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 2: Serious adverse events" data-id="CD012066-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_t/tCD012066-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 2: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/references#CD012066-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012066-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/urn:x-wiley:14651858:media:CD012066:CD012066-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 3: Quality of life as measured by the St George's Respiratory Questionnaire (SGRQ) total score change from baseline" data-id="CD012066-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_t/tCD012066-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 3: Quality of life as measured by the St George's Respiratory Questionnaire (SGRQ) total score change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/references#CD012066-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012066-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/urn:x-wiley:14651858:media:CD012066:CD012066-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 4: Trough FEV1 mean change (litres)" data-id="CD012066-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_t/tCD012066-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 4: Trough FEV<sub>1</sub> mean change (litres) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/references#CD012066-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012066-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/urn:x-wiley:14651858:media:CD012066:CD012066-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 5: Pneumonia" data-id="CD012066-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_t/tCD012066-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 5: Pneumonia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/references#CD012066-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012066-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/urn:x-wiley:14651858:media:CD012066:CD012066-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 6: All‐cause death" data-id="CD012066-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_t/tCD012066-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 6: All‐cause death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/references#CD012066-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012066-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/urn:x-wiley:14651858:media:CD012066:CD012066-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 7: SGRQ improvement ≥ 4 points" data-id="CD012066-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_t/tCD012066-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 7: SGRQ improvement ≥ 4 points </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/references#CD012066-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012066-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/urn:x-wiley:14651858:media:CD012066:CD012066-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 8: Exacerbations (fixed‐effect sensitivity)" data-id="CD012066-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_t/tCD012066-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 8: Exacerbations (fixed‐effect sensitivity) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/references#CD012066-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012066-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/urn:x-wiley:14651858:media:CD012066:CD012066-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 9: Serious adverse events (fixed‐effect sensitivity)" data-id="CD012066-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_t/tCD012066-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 9: Serious adverse events (fixed‐effect sensitivity) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/references#CD012066-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012066-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/urn:x-wiley:14651858:media:CD012066:CD012066-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 10: SGRQ mean change (fixed‐effect sensitivity)" data-id="CD012066-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_t/tCD012066-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 10: SGRQ mean change (fixed‐effect sensitivity) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/references#CD012066-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012066-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/urn:x-wiley:14651858:media:CD012066:CD012066-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 11: Trough FEV1 mean change (fixed‐effect sensitivity)" data-id="CD012066-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_t/tCD012066-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS), Outcome 11: Trough FEV<sub>1</sub> mean change (fixed‐effect sensitivity) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/references#CD012066-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/media/CDSR/CD012066/image_n/nCD012066-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012066-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>LAMA plus LABA versus LABA plus ICS for stable COPD</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people with stable COPD<br/><b>Setting:</b> outpatient. Studies were conducted in &gt; 50 countries including low‐, medium‐, and high‐income countries from all continents<br/><b>Intervention:</b> LAMA+LABA<br/><b>Comparison:</b> LABA+ICS </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>LABA+ICS</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>LAMA+LABA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations (number of people experiencing ≥ 1 exacerbations)</p> <p>Follow‐up: 6 to 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>291 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>272 per 1000 (243 to 303)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.91<br/>(0.78 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,960<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a‐e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low OR means favourable outcome</p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (number of people experiencing ≥ 1 SAEs)</p> <p>Follow‐up: 6 to 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000 (136 to 166)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.02<br/>(0.91 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,183<br/>(18 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High<sup>b,c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low OR means favourable outcome. Herth 2020 was discarded as no events were reported in either arm. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life as measured by SGRQ total score change from baseline (MD)</p> <p>Follow‐up: 12 to 52 weeks</p> <p>Scale 0 to 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.57</p> <p>(1.36 lower to 0.21 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,437</p> <p>(9 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a‐e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low MD means favourable outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trough FEV<sub>1</sub> change from baseline </p> <p>Follow‐up: 6 to 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.07 L</p> <p>(0.05 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,681</p> <p>(12 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a,b,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High MD means favourable outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia</p> <p>Follow‐up: 12 to 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000 (24 to 33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.61<br/>(0.52 to 0.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,829<br/>(14 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High<sup>b,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low OR means favourable outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause death</p> <p>Follow‐up: 6 to 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000 (11 to 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.35<br/>(1.05 to 1.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,510<br/>(15 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b,d,e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low OR means favourable outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SGRQ total score change from baseline</p> <p>(≥ 4 points, MCID)</p> <p>Follow‐up: 26 to 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>373 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>387 per 1000 (349 to 427)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.06</p> <p>(0.90 to 1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,614</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a‐e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High OR means favourable outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>absolute risk</b> (and its 95% CI) of LAMA+LABA group is based on the assumed risk in the LABA+ICS group and the <b>OR</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>ICS:</b> inhaled corticosteroid; <b>LABA:</b> long‐acting beta‐agonist; <b>LAMA:</b> long‐acting muscarinic antagonist; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>SGRQ:</b> St. George's Respiratory Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of effect but may be substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>There was a considerable heterogeneity, I<sup>2</sup> &gt; 50%.<br/><sup>b</sup>Studies varied in their inclusion criteria around recent history of exacerbation, baseline percentage predicted FEV<sub>1</sub> and exclusion of asthma. No indirectness downgrades, but impacts interpretation and applicability of results (see <a href="#CD012066-sec-0068">Discussion</a>).<br/><sup>c</sup>Confidence interval includes benefit of either treatment but lies within predefined threshold for clinical importance (0.7 to 1.5 for OR outcomes; 4‐point MCID for SGRQ) ‐ no downgrade for imprecision<br/><sup>d</sup>No downgrades for publication bias. Funnel plots examined for primary outcomes (exacerbations, serious adverse events, SGRQ, FEV<sub>1</sub>) do not show obvious asymmetry (see Figure 3; Figure 3; Figure 4; Figure 6). Nearly all studies included in pneumonia and all‐cause death analyses. Only 4 studies included in SGRQ 4+ change analysis but not specified in most studies. <br/><sup>e</sup>No downgrades for risk of bias. Across outcomes, all or almost all studies were at high risk of 'other' bias due to conflicts of interest, and studies contributing between 18.5% and 35.9% of the analysis weight were rated high risk of bias in at least one other domain. We did not prespecify a threshold or specific domains for downgrading, but considered it insufficient to downgrade if studies contributing more than half the analysis weight were at low or unclear risk of bias in all but the 'other' domain.<br/><sup>f</sup>There was imprecision due to a low number of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full#CD012066-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012066-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LAMA+LABA</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LABA+ICS</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Key inclusion criteria</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up duration (weeks)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean/median age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number randomised</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0001" title="BeehKM , DeromE , Echave-SustaetaJ , GrönkeL , HamiltonA , ZhaiD , et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study). International Journal of Chronic Obstructive Pulmonary Disease2016;11:193-205. [DOI: 10.2147/COPD.S95055] [PMID: 26893551]DeromE , BeehK , Echave-SustaetaJ , GrönkeL , ZhaiD , BjermerL . Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use. European Respiratory Journal2016;48:PA978. [DOI: 10.1183/13993003.congress-2016]">Beeh 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium/olodaterol (2.5/5 μg) or tiotropium/olodaterol (5/5 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/250 μg) twice daily or salmeterol/fluticasone (50/500 μg) twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 80% Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 × 4 time periods (cross‐over)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0002" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umeclidinium/vilanterol (62.5/25 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/250 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 70%, mMRC ≥ 2, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>707</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0003" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]">Donohue 2015b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umeclidinium/vilanterol (62.5/25 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/250 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 70%, mMRC ≥ 2, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>700</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0004" title="Ferguson GT,  Rabe KF,  Martinez FJ,  Fabbri LM,  Wang C,  Ichinose M,  et al . Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respiratory Medicine2018;10:747-58. [DOI: 10.1016/S2213-2600(18)30327-8] [PMID: 30232048]JPRN-JapicCTI-184079. A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort Turbuhaler as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PT010006). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184079. JPRN-JapicCTI-184080. A Randomized, Double-Blind, Parallel-Group, 28-Week, Chronic-Dosing, Multi-Center, Extension Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With Symbicort Turbuhaler as an Active Control (PT010007). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184080. NCT03262012. Study to assess the safety and efficacy of PT010, PT003, and PT009 in Japanese subjects with COPD compared with Symbicort Turbohaler. ClinicalTrials.gov/show/NCT03262012 (first posted 25 August 2017). ">Ferguson 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycopyrronium/formoterol fumarate (18/9.6 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol/budesonide/ fumarate (160/4.8 μg)  twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAT ≥ 10, %pred FEV<sub>1</sub> 25% to 80%, not required to have exacerbation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>943</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0005" title="Frith PA,  Ashmawi S,  Krishnamurthy S,  Gurgun A,  Hristoskova S,  Pilipovic V,  et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology2018;12:1152-9. [DOI: 10.1111/resp.13374] [PMID: 30074294]">Frith 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycopyrronium/indacaterol (50/110 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAT ≥ 10, %pred FEV1 30% to 80%, Ex(+)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>502</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0006" title="Herth F,  Hohlfeld JM,  Haas J,  Hoz A,  Jin X,  Kreitner K-F,  et al. The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD. BMJ Open Respiratory Research2020;7(1):e000741. [DOI: 10.1136/bmjresp-2020-000741] [PMID: 33268341]">Herth 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium/olodaterol (5/5 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone  (50/500 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> &lt; 70%, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0007" title="HoshinoM , OhtawaJ , AkitsuK . Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics2015;30:128-33. [DOI: 10.1016/j.pupt.2014.08.002] [PMID: 25183687]">Hoshino 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium/indacaterol (18/150 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/250 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 80%, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0008" title="LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. European Respiratory Journal2018;52:PA4385. [DOI: 10.1183/13993003.congress-2018.PA4385]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. European Respiratory Journal2018;52:PA4384. [DOI: 10.1183/13993003.congress-2018.PA4384]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ . Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. Pneumologie2019;73(Suppl 1):[no pagination]. Lipson DA,  Barnhart F,  Brealey N,  Brooks J,  Criner GJ,  Day NC,  et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine2018;378(18):1671-80. [DOI: 10.1056/NEJMoa1713901] [PMID: 29668352]">Lipson 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umeclidinium/vilanterol (62.5/25 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vilanterol/fluticasone furoate (25/100 μg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAT ≥ 10, %pred FEV<sub>1</sub> &lt; 80%, Ex(+) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6204</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0009" title="MagnussenH , MaltaisF , SchmidtH , KestenS , MetzdorfN . Comparison of tiotropium+salmeterol vs. fluticasone+salmeterol on lung volumes, exercise tolerance and locus of symptom limitation. American Journal of Respiratory and Critical Care Medicine2010;181:A4472. MagnussenH , PaggiaroP , SchmidtH , KestenS , MetzdorfN , MaltaisF . Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respiratory Medicine2012;106(10):1413-20. [DOI: 10.1016/j.rmed.2012.05.011] [PMID: 22749044]">Magnussen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium/salmeterol (18/50 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> ≤ 65%, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 x 2 time periods (cross‐over)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>344</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0010" title="Mostafa TM,  El-Azab GA,  Atia GA,  Lotfy NS. The effectiveness of 3 combined therapeutic regimens in Egyptian patients with moderate-to-severe chronic obstructive pulmonary disease: a randomized double-blind prospective pilot study. Current Therapeutic Research Clinical and Experimental2021;94:100625. [DOI: 10.1016/j.curtheres.2021.100625] [PMID: 34306265]">Mostafa 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium (18 μg) once daily/formoterol (9 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol/budesonide (160/4.5 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 80%, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0011" title="NCT03240575. The ENERGITO 2 study compares 2 inhaled medicines for chronic obstructive pulmonary disease (COPD). One medicine is a combination of tiotropium and olodaterol (Stiolto) taken using the Respimat inhaler and the other medicine is a combination of fluticasone and salmeterol taken using the Diskus. ClinicalTrials.gov/show/NCT03240575 (first posted 7 August 2017). ">NCT03240575</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium (5μg)/olodaterol (5μg) once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50μg/250μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 80%, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>302</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0012" title="RabeKF , TimmerW , SagkriotisA , VielK . Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest2008;134(2):255-62. [DOI: 10.1378/chest.07-2138] [PMID: 18403672]RabeKF , TimmerW , SagriotisA , VielK . Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. In: European Respiratory Society 15th Annual Congress; 2005 Sep 17-20; Copenhagen. 2005. ">Rabe 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium/formoterol (18/24 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> ≤ 65%, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>605</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0013" title="Rabe KF,  Martinez FJ,  Ferguson GT, Wang C,  Singh D,  Wedzicha JA,  et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New England Journal of Medicine2020;383(1):35-48. [DOI: 10.1056/NEJMoa1916046] [PMID: 32579807]">Rabe 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Glycopyrronium/formoterol (9/4.8 µg)  twice daily.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol/budesonide (4.8/160 µg) twice daily.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 25‐65%, CAT ≥ 10, Ex(+) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4294</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0014" title="SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. European Respiratory Journal2014;44(Suppl 58):P290. SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulmonary Medicine2015;15:91. [DOI: 10.1186/s12890-015-0092-1] [PMID: 26286141]">Singh 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umeclidinium/vilanterol (62.5/25 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 70%, mMRC ≥ 2, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>717</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0015" title="BatemanE , VogelmeierC , ChenH , BanerjiD . Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study. American College of Chest Physicians2014;145(3):409A. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 demonstrates superior lung function compared to twice-daily salmeterol/fluticasone in all subgroups of COPD patients: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4273. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 improves breathlessness and reduces rescue medication use compared to twice-daily salmeterol/fluticasone in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A2433. MezziK , PallanteJ , AlagappanV , ChenH , BanerjiD . Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β2-agonist/inhaled corticosteroid (LABA/ICS): the ILLUMINATE study. Chest2014;145(3):424A. VogelmeierC , BatemanE , PallanteJ , BryantH , AlagappanVD , AndreaP , et al. Once-daily QVA149 provides superior bronchodilation and improves lung function versus twice-daily fluticasone/salmeterol in COPD patients: the ILLUMINATE study. British Thoracic Society Winter Meeting2012;67:A149, P194. VogelmeierC , BatemanED , PallanteJ , BryantH , AlagappanV , D'Andrea, et al. QVA149 once daily is safe and well tolerated in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1477. VogelmeierCD , BatemanED , D'AndreaP , MezziK , ChenH , BanerjiD , et al. Once-daily QVA149 is more effective than twice-daily salmeterol/fluticasone in improving lung function, in patients with severe chronic obstructive pulmonary disease (COPD): the illuminate study. American Journal of Respiratory and Critical Care Medicine2014;189:A3763. VogelmeierCF , BatemanED , PallanteJ , AlagappanVK , D'AndreaP , ChenH , et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respiratory Medicine2013;1(1):51-60. [DOI: 10.1016/S2213-2600(12)70052-8] [PMID: 24321804]">Vogelmeier 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indacaterol/glycopyrronium bromide (110/50 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 80%, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>523</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0016" title="GreulichT , KostikasK , GagaM , Aalamian-MattheisM , LossiNS , Patalano  F, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. International Journal of Chronic Obstructive Pulmonary Disease2018;13:1229-37. [DOI: 10.2147/COPD.S159732] [PMID: 29713156]VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenA , et al. The efficacy and safety of aclidinium/formoterol fixed-dose combination compared with salmeterol/fluticasone in patients with COPD: results from a phase III study. American Journal of Respiratory and Critical Care Medicine2015;191:A3974. VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenAM , et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal2016;48(4):1030-9. [DOI: 10.1183/13993003.00216-2016] [PMID: 27492833]">Vogelmeier 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aclidinium/formoterol (400/12 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> &lt; 80%, CAT ≥ 10, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>933</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0017" title="VogelmeierCF , GagaM , Aalamian-MattheisM , GreulichT , MarinJM , CastellaniW , et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research2018;18(1):140. [DOI: 10.1186/s12931-017-0622-x] [PMID: 28720132]">Vogelmeier 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycopyrronium/Indacaterol (50/110 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>any</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 50% ‐80%, mMRC ≥ 1, Ex(+) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1083</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0018" title="KwaijtaalM , WedzichaJ , DecramerM , VestboJ , BanerjiD . Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. Respirology  2014;TP:177. WedzichaJ , VestboJ , GallagherN , BanerjiD . A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study. Chest2014;145(3):408A. WedzichaJA , BanerjiD , ChapmanKR , VestboJ , RocheN , AyersRT , et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. New England Journal of Medicine2016;374(23):2222-34. [DOI: 10.1056/NEJMoa1516385] [PMID: 27181606]">Wedzicha 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indacaterol/glycopyrronium bromide (110/50 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 25% to 60%, mMRC ≥ 2, Ex(+) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3362</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012066-bbs2-0019" title="ZhongN , WangC , ZhouX , ZhangN , HumphriesM , WangL , et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2015;10:1015-26. [DOI: 10.2147/COPD.S84436] [PMID: 26082625]">Zhong 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indacaterol/glycopyrronium bromide (110/50 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol/fluticasone (50/500 μg) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%pred FEV<sub>1</sub> 30% to 80%, mMRC ≥ 2, Ex(‐) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>744</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>%pred FEV<sub>1</sub>:</b> % predicted forced expiratory volume in one second; <b>CAT:</b> chronic obstructive pulmonary disease assessment test; <b>Ex(‐):</b> without recent exacerbation; <b>Ex(+):</b> with recent exacerbation; <b>LABA:</b> long‐acting beta‐agonist; <b>LAMA:</b> long‐acting muscarinic antagonist; <b>mMRC:</b> modified Medical Research Council dyspnoea scale </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full#CD012066-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012066-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">ORBIT matrix of outcome reporting across included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign=""> <p><b>Objective or semi‐objective outcomes (investigator‐assessed)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Subjective outcomes (patient‐reported)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Exacerbations</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SAEs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trough FEV<sub>1</sub> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pneumonia</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>All‐cause death</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SGRQ (mean)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SGRQ ≥ 4 unit benefit</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Indacaterol/glycopyrronium studies</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0005" title="Frith PA,  Ashmawi S,  Krishnamurthy S,  Gurgun A,  Hristoskova S,  Pilipovic V,  et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology2018;12:1152-9. [DOI: 10.1111/resp.13374] [PMID: 30074294]"><b>Frith 2018</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0015" title="BatemanE , VogelmeierC , ChenH , BanerjiD . Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study. American College of Chest Physicians2014;145(3):409A. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 demonstrates superior lung function compared to twice-daily salmeterol/fluticasone in all subgroups of COPD patients: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4273. BatemanED , VogelmeierC , PallanteJ , BryantH , AlagappanV , D'AndreaP , et al. Once-daily QVA149 improves breathlessness and reduces rescue medication use compared to twice-daily salmeterol/fluticasone in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A2433. MezziK , PallanteJ , AlagappanV , ChenH , BanerjiD . Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β2-agonist/inhaled corticosteroid (LABA/ICS): the ILLUMINATE study. Chest2014;145(3):424A. VogelmeierC , BatemanE , PallanteJ , BryantH , AlagappanVD , AndreaP , et al. Once-daily QVA149 provides superior bronchodilation and improves lung function versus twice-daily fluticasone/salmeterol in COPD patients: the ILLUMINATE study. British Thoracic Society Winter Meeting2012;67:A149, P194. VogelmeierC , BatemanED , PallanteJ , BryantH , AlagappanV , D'Andrea, et al. QVA149 once daily is safe and well tolerated in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1477. VogelmeierCD , BatemanED , D'AndreaP , MezziK , ChenH , BanerjiD , et al. Once-daily QVA149 is more effective than twice-daily salmeterol/fluticasone in improving lung function, in patients with severe chronic obstructive pulmonary disease (COPD): the illuminate study. American Journal of Respiratory and Critical Care Medicine2014;189:A3763. VogelmeierCF , BatemanED , PallanteJ , AlagappanVK , D'AndreaP , ChenH , et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respiratory Medicine2013;1(1):51-60. [DOI: 10.1016/S2213-2600(12)70052-8] [PMID: 24321804]"><b>Vogelmeier 2013</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0017" title="VogelmeierCF , GagaM , Aalamian-MattheisM , GreulichT , MarinJM , CastellaniW , et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research2018;18(1):140. [DOI: 10.1186/s12931-017-0622-x] [PMID: 28720132]"><b>Vogelmeier 2017</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0018" title="KwaijtaalM , WedzichaJ , DecramerM , VestboJ , BanerjiD . Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. Respirology  2014;TP:177. WedzichaJ , VestboJ , GallagherN , BanerjiD . A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study. Chest2014;145(3):408A. WedzichaJA , BanerjiD , ChapmanKR , VestboJ , RocheN , AyersRT , et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. New England Journal of Medicine2016;374(23):2222-34. [DOI: 10.1056/NEJMoa1516385] [PMID: 27181606]"><b>Wedzicha 2016</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0019" title="ZhongN , WangC , ZhouX , ZhangN , HumphriesM , WangL , et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2015;10:1015-26. [DOI: 10.2147/COPD.S84436] [PMID: 26082625]"><b>Zhong 2015</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Umeclidinium/vilanterol studies</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0002" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]"><b>Donohue 2015a</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0003" title="DonohueJ , WorsleyS , ZhuCQ , HardakerL , ChurchA . Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest2014;146(4):73A. DonohueJF , WorsleyS , ZhuCQ , HardakerL , ChurchA . Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine2015;109(7):870-81. [DOI: 10.1016/j.rmed.2015.04.018] [PMID: 26006754]"><b>Donohue 2015b</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0008" title="LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. European Respiratory Journal2018;52:PA4385. [DOI: 10.1183/13993003.congress-2018.PA4385]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ , et al. Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. European Respiratory Journal2018;52:PA4384. [DOI: 10.1183/13993003.congress-2018.PA4384]LipsonDA , BarnhartF , BoucotI , CrimC , BrealeyN , CrinerGJ . Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: pre-specified analysis on lung function and health status from the IMPACT trial. Pneumologie2019;73(Suppl 1):[no pagination]. Lipson DA,  Barnhart F,  Brealey N,  Brooks J,  Criner GJ,  Day NC,  et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine2018;378(18):1671-80. [DOI: 10.1056/NEJMoa1713901] [PMID: 29668352]"><b>Lipson 2018</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0014" title="SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. European Respiratory Journal2014;44(Suppl 58):P290. SinghD , WorsleyS , ZhuCQ , HardakerL , ChurchA . Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulmonary Medicine2015;15:91. [DOI: 10.1186/s12890-015-0092-1] [PMID: 26286141]"><b>Singh 2015</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Other LAMA/LABA inhaler studies</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0001" title="BeehKM , DeromE , Echave-SustaetaJ , GrönkeL , HamiltonA , ZhaiD , et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study). International Journal of Chronic Obstructive Pulmonary Disease2016;11:193-205. [DOI: 10.2147/COPD.S95055] [PMID: 26893551]DeromE , BeehK , Echave-SustaetaJ , GrönkeL , ZhaiD , BjermerL . Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use. European Respiratory Journal2016;48:PA978. [DOI: 10.1183/13993003.congress-2016]"><b>Beeh 2016</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0004" title="Ferguson GT,  Rabe KF,  Martinez FJ,  Fabbri LM,  Wang C,  Ichinose M,  et al . Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respiratory Medicine2018;10:747-58. [DOI: 10.1016/S2213-2600(18)30327-8] [PMID: 30232048]JPRN-JapicCTI-184079. A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort Turbuhaler as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PT010006). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184079. JPRN-JapicCTI-184080. A Randomized, Double-Blind, Parallel-Group, 28-Week, Chronic-Dosing, Multi-Center, Extension Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With Symbicort Turbuhaler as an Active Control (PT010007). www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-184080. NCT03262012. Study to assess the safety and efficacy of PT010, PT003, and PT009 in Japanese subjects with COPD compared with Symbicort Turbohaler. ClinicalTrials.gov/show/NCT03262012 (first posted 25 August 2017). "><b>Ferguson 2018</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0006" title="Herth F,  Hohlfeld JM,  Haas J,  Hoz A,  Jin X,  Kreitner K-F,  et al. The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD. BMJ Open Respiratory Research2020;7(1):e000741. [DOI: 10.1136/bmjresp-2020-000741] [PMID: 33268341]"><b>Herth 2020</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0007" title="HoshinoM , OhtawaJ , AkitsuK . Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics2015;30:128-33. [DOI: 10.1016/j.pupt.2014.08.002] [PMID: 25183687]"><b>Hoshino 2015</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0009" title="MagnussenH , MaltaisF , SchmidtH , KestenS , MetzdorfN . Comparison of tiotropium+salmeterol vs. fluticasone+salmeterol on lung volumes, exercise tolerance and locus of symptom limitation. American Journal of Respiratory and Critical Care Medicine2010;181:A4472. MagnussenH , PaggiaroP , SchmidtH , KestenS , MetzdorfN , MaltaisF . Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respiratory Medicine2012;106(10):1413-20. [DOI: 10.1016/j.rmed.2012.05.011] [PMID: 22749044]"><b>Magnussen 2012</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0010" title="Mostafa TM,  El-Azab GA,  Atia GA,  Lotfy NS. The effectiveness of 3 combined therapeutic regimens in Egyptian patients with moderate-to-severe chronic obstructive pulmonary disease: a randomized double-blind prospective pilot study. Current Therapeutic Research Clinical and Experimental2021;94:100625. [DOI: 10.1016/j.curtheres.2021.100625] [PMID: 34306265]"><b>Mostafa 2021</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0011" title="NCT03240575. The ENERGITO 2 study compares 2 inhaled medicines for chronic obstructive pulmonary disease (COPD). One medicine is a combination of tiotropium and olodaterol (Stiolto) taken using the Respimat inhaler and the other medicine is a combination of fluticasone and salmeterol taken using the Diskus. ClinicalTrials.gov/show/NCT03240575 (first posted 7 August 2017). "><b>NCT03240575</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0012" title="RabeKF , TimmerW , SagkriotisA , VielK . Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest2008;134(2):255-62. [DOI: 10.1378/chest.07-2138] [PMID: 18403672]RabeKF , TimmerW , SagriotisA , VielK . Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. In: European Respiratory Society 15th Annual Congress; 2005 Sep 17-20; Copenhagen. 2005. "><b>Rabe 2008</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0013" title="Rabe KF,  Martinez FJ,  Ferguson GT, Wang C,  Singh D,  Wedzicha JA,  et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New England Journal of Medicine2020;383(1):35-48. [DOI: 10.1056/NEJMoa1916046] [PMID: 32579807]"><b>Rabe 2020</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012066-bbs2-0016" title="GreulichT , KostikasK , GagaM , Aalamian-MattheisM , LossiNS , Patalano  F, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. International Journal of Chronic Obstructive Pulmonary Disease2018;13:1229-37. [DOI: 10.2147/COPD.S159732] [PMID: 29713156]VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenA , et al. The efficacy and safety of aclidinium/formoterol fixed-dose combination compared with salmeterol/fluticasone in patients with COPD: results from a phase III study. American Journal of Respiratory and Critical Care Medicine2015;191:A3974. VogelmeierC , PaggiaroPL , DorcaJ , SliwinskiP , MalletM , KirstenAM , et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal2016;48(4):1030-9. [DOI: 10.1183/13993003.00216-2016] [PMID: 27492833]"><b>Vogelmeier 2016</b> </a> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>X</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Outcomes shown are those included in the summary of findings table. Outcomes are classed as objective or subjective for the purposes of risk of bias assessment to consider differences in performance and detection bias. </p> <p><b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>ORBIT:</b> outcome reporting bias in trials; <b>SAEs:</b> serious adverse events; <b>SGRQ:</b> St George’s Respiratory Questionnaire </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">ORBIT matrix of outcome reporting across included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full#CD012066-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012066-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sponsor list for chronic obstructive pulmonary disease studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sponsor</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Record count</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% of 1723</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GlaxoSmithKline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Novartis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AstraZeneca</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Boehringer Ingelheim</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pfizer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nycomed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.84</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chiesi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Almirall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.09</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Merck</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.74</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Web of Science Core Collection, advanced search for "TI=(COPD) AND TS=(inhal*)" without any restriction hit 1723 reports as of 13 June 2016. "Results analysis" &gt; "Source Titles" output the table above. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sponsor list for chronic obstructive pulmonary disease studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/full#CD012066-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012066-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20960</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.78, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Indacaterol/glycopyrronium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.63, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Umeclidinium/vilanterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.03, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Other LAMA/LABA inhalers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.87, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Indacaterol/glycopyrronium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.76, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Umeclidinium/vilanterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.73, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Other LAMA/LABA inhalers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.92, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Quality of life as measured by the St George's Respiratory Questionnaire (SGRQ) total score change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐1.36, 0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Indacaterol/glycopyrronium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.29 [‐2.08, ‐0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Umeclidinium/vilanterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.02, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Other LAMA/LABA inhalers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.14 [‐4.06, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Trough FEV<sub>1</sub> mean change (litres) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.05, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Indacaterol/glycopyrronium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.05, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Umeclidinium/vilanterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.04, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Other LAMA/LABA inhalers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.02, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.52, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Indacaterol/glycopyrronium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.44, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Umeclidinium/vilanterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.50, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Other LAMA/LABA inhalers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.43, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 All‐cause death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.05, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Indacaterol/glycopyrronium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.59, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Umeclidinium/vilanterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.00, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Other LAMA/LABA inhalers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.94, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 SGRQ improvement ≥ 4 points <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.90, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Indacaterol/glycopyrronium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.09, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Umeclidinium/vilanterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.89, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Other LAMA/LABA inhalers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.79, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Exacerbations (fixed‐effect sensitivity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20960</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.87, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Indacaterol/glycopyrronium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.63, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Umeclidinium/vilanterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.03, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Other LAMA/LABA inhalers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.87, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Serious adverse events (fixed‐effect sensitivity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.95, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Indacaterol/glycopyrronium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.75, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Umeclidinium/vilanterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.99, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Other LAMA/LABA inhalers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.92, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 SGRQ mean change (fixed‐effect sensitivity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.02, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Indacaterol/glycopyrronium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.29 [‐2.08, ‐0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Umeclidinium/vilanterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.02, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 Other LAMA/LABA inhalers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐1.01, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Trough FEV<sub>1</sub> mean change (fixed‐effect sensitivity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.05, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Indacaterol/glycopyrronium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.05, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Umeclidinium/vilanterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.05, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 Other LAMA/LABA inhalers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.04, 0.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012066.pub3/references#CD012066-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012066.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012066-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012066-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012066-note-0016">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012066-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD012066-note-0010">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012066-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="nl#CD012066-note-0018">Nederlands</a> </li> <li class="section-language"> <a class="" href="pl#CD012066-note-0015">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD012066-note-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012066-note-0008">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012066-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012066\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012066\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012066\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012066\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012066\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012066.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012066.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012066.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012066.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012066.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740713972098"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012066.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740713972102"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012066.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d634fcb7c937a',t:'MTc0MDcxMzk3Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 